Suche Bilder Maps Play YouTube News Gmail Drive Mehr »
Anmelden
Nutzer von Screenreadern: Klicken Sie auf diesen Link, um die Bedienungshilfen zu aktivieren. Dieser Modus bietet die gleichen Grundfunktionen, funktioniert aber besser mit Ihrem Reader.

Patente

  1. Erweiterte Patentsuche
VeröffentlichungsnummerUS5624802 A
PublikationstypErteilung
AnmeldenummerUS 08/479,493
Veröffentlichungsdatum29. Apr. 1997
Eingetragen7. Juni 1995
Prioritätsdatum15. Okt. 1987
GebührenstatusBezahlt
Auch veröffentlicht unterUS5359100, US5571670, US5594118, US5614362
Veröffentlichungsnummer08479493, 479493, US 5624802 A, US 5624802A, US-A-5624802, US5624802 A, US5624802A
ErfinderMichael S. Urdea, Brian Warner, Thomas Horn
Ursprünglich BevollmächtigterChiron Corporation
Zitat exportierenBiBTeX, EndNote, RefMan
Externe Links: USPTO, USPTO-Zuordnung, Espacenet
Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US 5624802 A
Zusammenfassung
Linear or branched oligonucleotide multimers useful as amplifiers in biochemical assays which comprise (1) at least one first single-stranded oligonucleotide unit that is complementary to a single-stranded oligonucleotide sequence of interest, and (2) a multiplicity of second single-stranded oligonucleotide units that are complementary to a single-stranded labeled oligonucleotide. Amplified sandwich nucleic acid hybridizations and immunoassays using the multimers are exemplified.
Bilder(22)
Previous page
Next page
Ansprüche(39)
We claim:
1. A synthetic branched nucleic acid multimer having a minimum of three termini independently selected from 5' and 3' termini said multimer comprising:
(a) at least one first single-stranded oligonucleotide unit that is capable of hybridizing specifically to a first single-stranded nucleic acid sequence of interest; and
(b) a multiplicity of second single-stranded oligonucleotide units each of which is capable of hybridizing specifically to a second single-stranded nucleic acid sequence of interest, wherein the first single-stranded oligonucleotide unit is bonded directly or indirectly to the multiplicity of second single-stranded oligonucleotide units only via covalent bonds.
2. The nucleic acid multimer of claim 1 wherein the first oligonucleotide unit has a different sequence than the second oligonucleotide unit and the number of second oligonucleotide units is at least about two-fold the number of first oligonucleotide units.
3. The nucleic acid multimer of claim 1 wherein the first oligonucleotide unit is of about 15 to 50 bases and has a GC content in the range of about 40% to about 60% and the second oligonucleotide unit is of about 15 to 50 bases and has a GC content in the range of about 40% to about 60%.
4. The nucleic acid multimer of claim 1 wherein the nucleotide sequence of the first oligonucleotide unit is the same as the nucleotide sequence of the second oligonucleotide unit and the combined number of units is at least about 3.
5. The nucleic acid multimer of claim 1 wherein the multimer has a "comb-like" branched structure and comprises an oligonucleotide backbone with one or more pendant chains composed of one or more oligonucleotide units.
6. The nucleic acid multimer of claim 1 wherein the multimer has a "fork-like" branched structure.
7. The nucleic acid multimer of claim 1 wherein the multimer is a DNA multimer.
8. The nucleic acid multimer of claim 1 wherein the multimer is an RNA multimer.
9. The nucleic acid multimer of claim 1 wherein either or both of the first and second single-stranded oligonucleotide units contains one or more modified nucleotides.
10. The nucleic acid multimer of claim 1 wherein the oligonucleotide units of the multimer are linked to each other through phosphodiester bonds.
11. The nucleic acid multimer of claim 1 wherein the oligonucleotide units of the multimer are linked to each other via a cross-linking agent.
12. The nucleic acid multimer of claim 11 wherein the cross-linking agent is covalently bonded to the oligonucleotide units of the multimer via N4 -modified cytosine bases.
13. The nucleic acid multimer of claim 1 wherein at least a portion of the oligonucleotide units of the multimer are linked via a multifunctional moiety derived from a compound of the formula: ##STR12## where R is an organic moiety, R1 is a hydroxyl protecting group that can be removed under conditions that do not remove synthetic nucleic acid from a solid phase and do not remove exocyclic nitrogen or phosphate protecting groups, X is a phosphorous-containing group that facilitates nucleic acid synthesis, Y is a radical derived from a nucleophilic group, and R2 is R1 or a blocking or protective group that can be removed and replaced with hydrogen without affecting R1.
14. The nucleic acid multimer of claim 1 wherein at least a portion of the oligonucleotide units are linked via a multifunctional moiety derived from a compound of the formula: ##STR13## where Z is a nucleophile, R1 is a protective group that is generally base-stable and acid sensitive, R2 is hydrogen or methyl, R3 is a protective group that can be removed and replaced with hydrogen without affecting R1, R5 is a phosphorus derivative that enables addition of nucleotides to the 5' position of an oligonucleotide chain during chemical synthesis, R6 is methyl, hydrogen, I, Br, or F, and X is an integer in the range of 1 to 8, inclusive.
15. The nucleic acid multimer of claim 1 wherein at least a portion of the oligonucleotide units are linked via a multifunctional moiety derived from a compound of the formula: ##STR14## where R is a hydroxyl protecting group, iPr is isopropyl, and R1 is methyl or beta-cyanoethyl.
16. The nucleic acid multimer of claim 1 wherein the first single-stranded nucleotide sequence of interest is analyte nucleic acid.
17. The nucleic acid multimer of claim 1 wherein the first single-stranded nucleotide sequence of interest is an oligonucleotide that is hybridized to analyte nucleic acid.
18. The nucleic acid multimer of claim 1 wherein the first single-stranded nucleotide sequence of interest is an oligonucleotide that is bound to a ligand.
19. The nucleic acid multimer of claim 1 wherein the second single-stranded nucleotide sequence of interest is a sequence of a single-stranded labeled oligonucleotide.
20. The nucleic acid multimer of claim 1 wherein the second single-stranded nucleotide sequence of interest is a sequence of an oligonucleotide unit of a second nucleic acid multimer.
21. The nucleic acid multimer of claim 1 wherein there is a chemically cleavable linker in each of the second single-stranded oligonucleotide units.
22. The nucleic acid multimer of claim 19 wherein there is a chemically cleavable linker in each of the second single-stranded oligonucleotide units.
23. The nucleic acid multimer of claim 21 wherein the linker includes a 1,2-diol group that is cleavable with a periodate.
24. The nucleic acid multimer of claim 22 wherein the linker includes a 1,2-diol group that is cleavable with a periodate.
25. The nucleic acid multimer of claim 23 wherein the linker has the formula: ##STR15##
26. The nucleic acid multimer of claim 24 wherein the linker has the formula: ##STR16##
27. A nucleic acid hybridization assay wherein:
(a) the multimer of claim 19 is hybridized via the first oligonucleotide unit to single-stranded analyte nucleic acid bound to a solid phase or to a single-stranded oligonucleotide bound to the analyte, or to a second multimer bound to the analyte;
(b) unbound multimer is removed;
(c) single-stranded labeled oligonucleotide is a hybridized to the multimer via the second oligonucleotide;
(d) unbound labeled oligonucleotide is removed;
(e) the presence of label bound to the multimer is detected.
28. The assay of claim 27 wherein the first oligonucleotide unit has a different sequence than the second oligonucleotide unit and the number of second oligonucleotide units is at least about two-fold the number of first oligonucleotide units.
29. The assay of claim 27 wherein the first oligonucleotide unit is of about 15 to 50 bases and has a GC content in the range of about 40% to about 60% and the second oligonucleotide unit is of about 15 to 50 bases and has a GC content in the range of about 40% to about 60%.
30. The assay of claim 27 wherein the nucleotide sequence of the first oligonucleotide unit is the same as the nucleotide sequence of the second oligonucleotide unit and the combined number of units is at least about 3.
31. The assay of claim 27 wherein the oligonucleotide units of the multimer are linked to each other through phosphodiester bonds.
32. The assay of claim 27 wherein the oligonucleotide units of the multimer are linked to each other via a cross-linking agent.
33. The assay of claim 32 wherein the cross-linking agent is covalently bonded to the oligonucleotide units of the multimer via N4 -modified cytosine bases.
34. The assay of claim 32 wherein at least a portion of the oligonucleotide units of the multimer are linked via a multifunctional moiety derived from a compound of the formula: ##STR17## where R is an organic moiety, R1 is a hydroxyl protecting group that can be removed under conditions that do not remove synthetic nucleic acid from a solid phase and do not remove exocyclic nitrogen or phosphate protecting groups, X is a phosphorous-containing group that facilitates nucleic acid synthesis, Y is a radical derived from a nucleophilic group, and R2 is R1 or a blocking or protective group that can be removed and replaced with hydrogen without affecting R1.
35. The assay of claim 27 wherein at least a portion of the oligonucleotide units are linked via a multifunctional moiety derived from a compound of the formula: ##STR18## where Z is a nucleophile, R1 is a protective group that is generally base-stable and acid sensitive, R2 is hydrogen or methyl, R3 is a protective group that can be removed and replaced with hydrogen without affecting R1, R5 is a phosphorus derivative that enables addition of nucleotides to the 5' position of an oligonucleotide chain during chemical synthesis, R6 is methyl, hydrogen, I, Br, or F, and X is an integer in the range of 1 to 8, inclusive.
36. The assay of claim 27 wherein at least a portion of the oligonucleotide units are linked via a multifunctional moiety derived from a compound of the formula: ##STR19## where R is a hydroxyl protecting group, iPr is isopropyl, and R1 is methyl or beta-cyanoethyl.
37. An immunoassay for an analyte molecule comprising:
(a) binding a ligand specifically and directly or indirectly to the analyte, wherein said ligand is an antibody having a single-stranded oligonucleotide bound thereto that is complementary to the first oligonucleotide unit of the multimer of claim 1;
(b) removing unbound ligand;
(c) hybridizing the multimer of claim 1 to the ligand;
(d) hybridizing a labeled oligonucleotide to the second oligonucleotide units of the bound multimer;
(e) removing unbound labeled oligonucleotide;
(f) detecting the presence of label bound to the bound multimer.
38. A synthetic branched nucleic acid multimer according to claim 1, wherein said multiplicity of second single-stranded oligonucleotide units comprises a multiplicity of different single-stranded oligonucleotide units.
39. A synthetic branched nucleic acid multimer according to claim 1, wherein said multiplicity of second single-stranded oligonucleotide units comprises a multiplicity of identical single-stranded oligonucleotide units.
Beschreibung
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 08/163,916 filed 8 Dec. 1993 now abandoned, which is a continuation of U.S. patent application Ser. No. 07/823,890, filed 22 Jan. 1992, now abandoned, which in turn is a divisional of U.S. patent application Ser. No. 07/340,031, filed 18 Apr. 1989, which issued as U.S. Pat. No. 5,124,246 on 23 Jun. 1992, which in turn was a continuation-in-part of U.S. patent application Ser. No. 07/252,638, filed 30 Sep. 1988 and now abandoned, which in turn was a continuation-in-part of U.S. patent application Ser. No. 07/185,201, filed 22 Apr. 1988 and now abandoned, which in turn was a continuation-in-part of U.S. patent application Ser. No. 07/109,282, filed 15 Oct. 1987 and now abandoned. Additionally, an international application, No. 88/03664, was filed 14 Oct. 1988 based on U.S. patent applications Ser. Nos. 07/282,638, 07/185,201 and 07/109,282, and was published 5 May 1989 (Int. Pub. No. 89/03891). The disclosures of these related applications are hereby incorporated by reference.

DESCRIPTION

1. Technical Field

This invention is in the fields of nucleic acid chemistry and biochemical assays. More particularly, it relates to novel nucleic acid multimers and nucleic acid hybridization assays.

2. Background Art

Nucleic acid hybridizations are now commonly used in genetic research, biomedical research and clinical diagnostics. In the basic nucleic acid hybridization assay, single-stranded analyte nucleic acid (either DNA or RNA) is hybridized to a labeled nucleic acid probe, and resulting labeled duplexes are detected. Both radioactive and nonradioactive labels have been used.

Variations of this basic scheme have been developed to facilitate separation of the duplexes to be detected from extraneous materials and/or to amplify the signal that is detected.

Copending commonly owned U.S. Ser. No. 807,624, filed 11 Dec. 1985, describes a solution-phase nucleic acid hybridization assay in which the analyte nucleic acid is hybridized to a labeling probe set and to a capturing probe set. The probe-analyte complex is coupled by hybridization with a solid-supported capture probe that is complementary to the capture probe set. This permits the analyte nucleic acid to be removed from solution as a solid phase complex. Having the analyte in the form of a solid phase complex facilitates subsequent separation steps in the assay. The labeling probe set is complementary to a labeled probe that is bound through hybridization to the solid phase/analyte complex.

PCT Application 84/03520 and EPA 124221 describe a DNA hybridization assay in which: (1) analyte is annealed to a single-stranded DNA probe that has a tail that is complementary to an enzyme-labeled oligonucleotide, and (2) the resulting tailed duplex is hybridized to an enzyme-labeled oligonucleotide. The Enzo Biochem "Bio-Bridge" labeling system appears to be similar to the system described in these two patent applications. The "Bio-Bridge" system uses terminal deoxynucleotide transferase to add unmodified 3'-polyT-tails to a DNA probe. The polyT-tailed probe is hybridized to the target DNA sequence and then to a biotin-modified polyA.

EPA 204510 describes a DNA hybridization assay in which analyte DNA is contacted with a probe that has a tail, such as a polyT-tail, an amplifier strand that has a sequence, e.g., a polyA sequence, that hybridizes to the tail of the probe and is capable of binding a plurality of labeled strands.

The main problem with these prior hybridization assays is that they lack sufficient specificity and/or signal to be useful for detecting very low levels of analyte. A primary object of the present invention is to provide an amplifier for use in nucleic acid hybridizations that provides a high reproducible gain in signal, a high reproducible signal-to-noise ratio and low nonspecific binding, that is itself reproducible, and that is capable of combining specifically with a "universal" signal moiety and an analyte at low concentrations to form a stable complex.

Other aspects are to provide improved hybridization assays for hepatitis B virus (HBV), N. gonorrhoeae, penicillin and tetracycline resistance in N. gonorrhoeae, and Chlamydia trachomatis.

DISCLOSURE OF THE INVENTION

One aspect of the invention is a nucleic acid multimer comprising:

(a) at least one first single-stranded oligonucleotide unit that is capable of binding specifically to a first single-stranded nucleotide sequence of interest; and

(b) a multiplicity of second single-stranded oligonucleotide units that are capable of binding specifically to a second single-stranded nucleotide sequence of interest.

Another aspect of the invention is a nucleic acid hybridization assay in which (1) the above-described multimer is hybridized via the first oligonucleotide unit to single-stranded analyte nucleic acid or an oligonucleotide bound to the analyte or to another multimer bound to the analyte, and (2) a multiplicity of single-stranded labeled oligonucleotides are then hybridized to the multimer via the multiplicity of second oligonucleotide units.

Still another aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a solution-phase sandwich hybridization assay for hepatitis B virus (HBV) comprising (a) a first segment having a nucleotide sequence complementary to a segment of the HBV genome and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer.

Yet another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a solution-phase sandwich hybridization assay for HBV comprising (a) a first segment having a nucleotide sequence complementary to a segment of the HBV genome and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase.

Still another aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a solution-phase sandwich hybridization assay for N. gonorrhoeae comprising (a) a first segment having a nucleotide sequence complementary to a segment of N. gonorrhoeae pilin DNA and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer.

Yet another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a solution-phase sandwich hybridization assay for N. gonorrhoeae comprising (a) a first segment having a nucleotide sequence complementary to a segment of N. gonorrhoeae pilin DNA and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase.

Still another aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a solution-phase sandwich hybridization assay for N. gonorrhoeae comprising (a) a first segment having a nucleotide sequence complementary to a segment of the N. gonorrhoeae genomic clone shown in FIG. 13 and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer.

Yet another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a solution-phase sandwich hybridization assay for N. gonorrhoeae comprising (a) a first segment having a nucleotide sequence complementary to a segment of the N. gonorrhoeae genomic clone shown in FIG. 13 and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase.

A further aspect of the invention is a DNA probe for detecting N. gonorrhoeae DNA said probe having a nucleotide sequence that is complementary to all or a portion of either strand of the N. gonorrhoeae genomic clone shown in FIG. 13.

A further aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a sandwich hybridization assay for the 7.3 kb N. gonorrhoeae family of plasmids carrying the beta-Lactamase TEM-1 gene or said gene comprising (a) a first segment having a nucleotide sequence complementary to a segment of said plasmid or said gene and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer.

Another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a sandwich hybridization assay for the 7.3 kb N. gonorrhoeae family of plasmids carrying the beta-Lactamase TEM-1 gene or said gene comprising (a) a first segment having a nucleotide sequence complementary to a segment of said plasmid or said gene and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase.

Another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a sandwich hybridization assay for the tetM gene in a tetracycline resistant organism comprising (a) a first segment having a nucleotide sequence complementary to a segment the tetM gene and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase.

A further aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a sandwich hybridization assay for the tetM gene in a tetracycline resistant organism comprising (a) a first segment having a nucleotide sequence complementary to a segment of the tetM gene and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer.

Still another aspect of the invention is a synthetic oligonucleotide useful as an amplifier probe in a solution-phase sandwich hybridization assay for Chlamydia trachomatis comprising (a) a first segment having a nucleotide sequence complementary to a segment of the Chlamydia pCHL2 plasmid and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer.

Yet another aspect of the invention is a synthetic oligonucleotide useful as a capture probe in a solution-phase sandwich hybridization assay for Chlamydia trachomatis comprising (a) a first segment having a nucleotide sequence complementary to a segment of the Chlamydia pCHL2 plasmid and (b) a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase.

Still another aspect of the invention is a solution sandwich DNA hybridization for detecting HBV DNA in an analyte comprising:

(a) contacting the analyte under hybridizing conditions with an excess of i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the HBV genome and a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the HBV genome and a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

Still another aspect of the invention is a solution sandwich DNA hybridization for detecting N. gonorrhoeae pilin DNA in an analyte comprising:

(a) contacting the analyte under hybridizing conditions with an excess of (i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of N. gonorrhoeae pilin DNA genome and a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of N. gonorrhoeae pilin DNA and a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

Still another aspect of the invention is a solution sandwich DNA hybridization for detecting N. gonorrhoeae DNA in an analyte comprising:

(a) contacting the analyte under hybridizing conditions with an excess of (i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the N. gonorrhoeae genomic clone shown in FIG. 14 and a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the N. gonorrhoeae genomic clone shown in FIG. 14 and a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

Another aspect of the invention is a DNA hybridization assay for detecting N. gonorrhoeae DNA in an analyte comprising contacting the analyte under hybridizing conditions with a DNA probe that is complementary to all or a portion of either strand of the N. gonorrhoeae genomic clone shown in FIG. 14 and detecting the presence of duplexes containing the DNA probe.

Still another aspect of the invention is a solution sandwich DNA hybridization for detecting Chlamydia trachomatis DNA in an analyte comprising:

(a) contacting the analyte under hybridizing conditions with an excess of i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the Chlamydia pCHL2 plasmid and a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the Chlamydia pCHL2 plasmid and a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

Still another aspect of the invention is a solution sandwich nucleic acid hybridization assay for detecting a first nucleic acid sequence that is part of a nucleic acid segment that includes a second nucleic acid sequence in a sample that contains said segment and another nucleic acid segment that comprises the first nucleic acid sequence but does not include the second nucleic acid sequence comprising:

(a) contacting the analyte under hybridizing conditions with an excess of (i) an amplifier probe oligonucleotide comprising a first segment that is complementary to one of the first nucleic acid sequence or the second nucleic acid sequence and a second segment that is complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment that is complementary to the other of the first nucleic acid sequence or the second nucleic acid sequence and a second segment that is complementary to an oligonucleotide bound to-a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

Yet another aspect of the invention is a solution sandwich DNA hybridization for detecting the 7.3 kb N. gonorrhoeae plasmid carrying the beta-Lactamase TEM-1 gene or said gene in an analyte comprising:

(a) contacting the analyte under hybridizing conditions with an excess of i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of said plasmid or said gene and a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to another segment of said plasmid or said gene and a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

Yet another aspect of the invention is a solution sandwich DNA hybridization for detecting tetM gene DNA suspected of containing DNA of a tetracycline resistant organism in an analyte comprising:

(a) contacting the analyte under hybridizing conditions with an excess of i) an amplifier probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to a segment of the tetM gene and a second segment having a nucleotide sequence complementary to an oligonucleotide unit of a nucleic acid multimer and (ii) a capture probe oligonucleotide comprising a first segment having a nucleotide sequence complementary to another segment of said tetM gene and a second segment having a nucleotide sequence complementary to an oligonucleotide bound to a solid phase;

(b) contacting under hybridizing conditions the product of step (a) with the oligonucleotide bound to the solid phase;

(c) thereafter separating materials not bound to the solid phase;

(d) contacting under hybridizing conditions the solid phase complex product of step (c) with the nucleic acid multimer, said multimer comprising (i) at least one oligonucleotide unit that is complementary to the second segment of the amplifier probe oligonucleotide and (ii) a multiplicity of second oligonucleotide units that are complementary to a labeled oligonucleotide;

(e) removing unbound multimer;

(f) contacting under hybridizing conditions the solid phase complex product of step (e) with the labeled oligonucleotide;

(g) removing unbound labeled oligonucleotide; and

(h) detecting the presence of label in the solid phase complex product of step (g).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the process for the enzymatic preparation of a linear nucleic acid multimer that is described in Example 1.

FIGS. 2A and 2B are schematic representations of the processes for the chemical preparation of linear and branched nucleic acid multimers that are described in Example 2.

FIG. 3 (Parts A-F), illustrate procedures used in making multimers having "comb-like" and/or bifurcated structures.

FIG. 4 is a schematic representation of the sandwich hybridization assay described in Example 3.

FIG. 5 is an autoradiogram showing the results of the dot blot screening tests described in the examples.

FIGS. 6-8 are bar graphs depicting the results of the tests on authentic HBV DNA samples that are described in Example 4.

FIG. 9 depicts schematically the multimers used in the assay described in Example 5.

FIG. 10 shows the DNA sequence of the coding strand of a portion of a 7.3 kb N. gonorrhoeae plasmid carrying the beta-Lactamase TEM-1 gene.

FIG. 11 shows partial nucleotide sequences of the capture and amplifier probes used in the TEM-1NH assay described in Example 6.

FIG. 12 shows partial nucleotide sequences of the capture and amplifier probes used in the TEM-1 assay described in Example 6.

FIG. 13 shows the nucleotide sequence for the tetM gene and partial nucleotide sequences (the 5' ends) of the capture and amplifier probes used in the term assay described in Example 8.

FIG. 14 is the DNA sequence of the N. gonorrhoeae genomic sequence SSJK1 described in Example 9.

FIG. 15 shows partial nucleotide sequences of the capture and amplifier probes used in the N. gonorrhoeae assay described in Example 9.

FIG. 16 shows partial nucleotide sequences of the capture and amplifier probes used in the HBV assay described on Example 10.

MODES FOR CARRYING OUT THE INVENTION Description of Multimers

The nucleic acid multimers of the invention are linear or branched polymers of the same repeating single-stranded oligonucleotide unit or different single-stranded oligonucleotide units. At least one of the units has a sequence, length, and composition that permits it to bind specifically to a first single-stranded nucleotide sequence of interest, typically analyte or an oligonucleotide bound to the analyte. In order to achieve such specificity and stability, this unit will normally be 15 to 50, preferably 15 to 30, nucleotides in length and have a GC content in the range of 40% to 60%. In addition to such unit(s), the multimer includes a multiplicity of units that are capable of hybridizing specifically and stably to a second single-stranded nucleotide of interest, typically a labeled oligonucleotide or another multimer. These units will also normally be 15 to 50, preferably 15 to 30, nucleotides in length and have a GC content in the range of 40% to 60%. When a multimer is designed to be hybridized to another multimer, the first and second oligonucleotide units are heterogeneous (different).

The total number of oligonucleotide units in the multimer will usually be in the range of 3 to 50, more usually 10 to 20. In multimers in which the unit that hybridizes to the nucleotide sequence of interest is different from the unit that hybridizes to the labeled oligonucleotide, the number ratio of the latter to the former will usually be 2:1 to 30:1, more usually 5:1 to 20:1, and preferably 10:1 to 15:1.

The oligonucleotide units of the multimer may be composed of RNA, DNA, modified nucleotides or combinations thereof.

The oligonucleotide units of the multimer may be covalently linked directly to each other through phosphodiester bonds or through interposed linking agents such as nucleic acid, amino acid, carbohydrate or polyol bridges, or through other cross-linking agents that are capable of cross-linking nucleic acid or modified nucleic acid strands. The site(s) of linkage may be at the ends of the unit (in either normal 3'-5' orientation or randomly oriented) and/or at one or more internal nucleotides in the strand. In linear multimers the individual units are linked end-to-end to form a linear polymer. In one type of branched multimer three or more oligonucleotide units emanate from a point of origin to form a branched structure. The point of origin may be another oligonucleotide unit or a multifunctional molecule to which at least three units can be covalently bound. In another type, there is an oligonucleotide unit backbone with one or more pendant oligonucleotide units. These Latter-type multimers are "fork-like", "comb-like" or combination "fork-" and "comb-like" in structure. The pendant units will normally depend from a modified nucleotide or other organic moiety having appropriate functional groups to which oligonucleotides may be conjugated or otherwise attached. The multimer may be totally linear, totally branched, or a combination of linear and branched portions. Preferably there will be at least two branch points in the multimer, more preferably at least 3, preferably 5 to 10. The multimer may include one or more segments of double-stranded sequences.

Synthesis of Multimers

The multimers may be prepared by cloning (if linear), enzymatic assembly, chemical cross-linking techniques, direct chemical synthesis or a combination thereof. In the case of linear multimers prepared by cloning, nucleic acid sequences that encode the entire multimer or fragments thereof can be made in single- or double-stranded form by conventional cloning procedures. When made in double-stranded form, the multimers/fragments are ultimately denatured to provide single-stranded multimers/fragments. Multimers may be cloned in single-stranded form using conventional single-stranded phage vectors such as M13. Fragments can be linked enzymatically or chemically to form the multimer. When assembled enzymatically, the individual units are ligated with a ligase such as T4 DNA or RNA ligase, as the case may be. When prepared by chemical cross-linking, the individual units may be synthesized with one or more nucleic acids that have been derivatized to have functional groups that provide linking sites or derivatized after the oligonucleotide has been synthesized to provide such sites. A preferred procedure for chemical cross-linking is to incorporate N4 -modified cytosine bases into the nucleotide as described in commonly owned copending U.S. application Ser. No. 945,876 filed 23 Dec. 1986, the disclosure of which is incorporated herein by reference.

When prepared by direct chemical synthesis oligonucleotides containing derivatized nucleic acids or equivalent multifunctional molecules whose functional groups are blocked are made by conventional oligonucleotide synthesis techniques. The functional groups are unblocked and oligonucleotide units are synthesized out from the unblocked site(s).

A generic structure for the molecules used to generate branch points in the multimers is as follows: ##STR1## where R is an organic moiety, preferably a nucleic acid, R1 is a hydroxyl protecting group that can be removed under conditions that do not remove synthetic nucleic acid from a solid phase and do not remove exocyclic nitrogen or phosphate protecting groups, X is a phosphorus-containing group that facilitates nucleic acid synthesis, such as a protected phosphoramidite, phosphonate or phosphate group, Y is a radical derived from a nucleophilic group such as an amino, hydroxyl, sulfhydryl or protected phosphate, and R2 is R1 or a blocking or protective group that can be removed and replaced with hydrogen without affecting R1. In molecules used to generate bifurcated or "fork-like" branching, R1 and R2 are the same; whereas in molecules used to generate "comb-like" branching, R2 is a blocking group that is stable in the presence of an R1 deblocking reagent. FIG. 3 schematically illustrates the procedures used to synthesize multimers having "comb-like" branches, "fork-like" branches, or combinations thereof.

Part A of FIG. 3 depicts a conventional oligonucleotide synthesis scheme for preparing a linear oligonucleotide, such as the automated phosphoramidite method (Warner et al., DNA (1984) 3:401). The dark block represents a solid support, N represents a nucleotide and p--N--OR1 (R1 is equivalent to R1 below), a conventional nucleotide derivative having appropriate protecting groups.

Part B shows the procedure for making a comb-like multimer. The compound ##STR2## represents a modified base of formula (2) below. An oligomer unit of desired size and sequence is synthesized and left on the support. One or more N4 -modified cytosine bases are then incorporated into the chain by said automated procedure. Preferably, the modified base has the formula ##STR3## where Z is a nucleophile such as --O--, --NH--, --S--, PO4 ═, and ##STR4## R1 is a blocking or protective group such as dimethoxytrityl (DMT) or pixyl that is generally basestable and acid sensitive, R2 is hydrogen or methyl, R3 is a blocking or protective group that can be removed and replaced with hydrogen without affecting R1 such as ##STR5## R5 is a phosphoramidite or other phosphorus derivative that enables addition of nucleotides to the 5' position of an oligonucleotide chain during chemical synthesis (e.g., a phosphodiester phosphotriester R6 is methyl, hydrogen, I, Br, or F, and X is an integer in the range of 1 to 8, inclusive. When more than one modified base is incorporated they are preferably spaced by intermediate bases in the chain, most preferably by a -TT- dimer. Additional oligonucleotide units may be incorporated into the backbone followed by additional modified bases and so forth.

The N4 nucleophile group is then deprotected (R3 is removed) and additional oligonucleotide units are generated therefrom by the automated procedure. Residual R1 groups at the chain terminii are removed and the branched "comb-like" multimer is cleaved from the support.

Part C of FIG. 3 depicts the general procedure for making "fork-like" multimers. Again, an oligomer unit of desired size and sequence is synthesized by conventional techniques and left on the support. A blocked, bifunctional phosphorus-containing group (represented as XP in Part C) such as a blocked phosphoramidite, is then incorporated into the chain by the automated procedure. Preferred bifunctional phosphorus-containing groups are blocked phosphoramidites of the formula ##STR6## where R is said hydroxyl protecting group, iPr is isopropyl, and R1 is methyl or beta-cyanoethyl. Most preferably R is DMT and R1 is beta-cyanoethyl.

Alternatively, the N4 -modified cytosine base where R1 =R2 (e.g., DMT) can be used.

The two protecting groups are then removed and additional oligonucleotide units are generated therefrom by the automated procedure. Residual R1 groups are removed and the bifurcated multimer is cleaved from the support.

Parts D and E depict procedures where two or more bifurcated multimers, "comb-like" multimers or combinations thereof are spliced together enzymatically or chemically. Generally, the bifurcated and/or "comb-like" multimers are prepared as above and removed from the support. They are then combined in solution using the enzymatic or chemical linkage procedures described above.

Part F shows the procedure for synthesizing a multiple "comb-like" multimer. This procedure is a variation of the procedure shown in Part B and involves incorporating modified bases in the dependent side chains and generating secondary oligonucleotide side chains therefrom.

Suitable cleavable linker molecules may be incorporated into the multimers at predetermined sites for the purpose of analyzing the structure of the multimer or as a means for releasing predetermined segments (such as the portion of the multimer that binds to the labeled oligonucleotide). Subsequent to multimer synthesis and purification these linkers can be cleaved specifically without additional degradation of the nucleotide structure of the multimer. A preferred type of linker molecule was designed to contain a 1,2-diol group (which can be cleaved selectively by periodates) as well as a protected hydroxyl and phosphoramidite derived hydroxyl group to permit the linker to be incorporated into any DNA fragment by standard phosphoramidite chemistry protocols. A preferred embodiment of such a linker is the compound: ##STR7## where DMT and iPr are as defined previously. After incorporation into a DNA fragment and complete deprotection the linker-containing fragment has the following structure: ##STR8## where DNA1 and DNA2 represent DNA subfragments which may be the same or different. Reaction of this fragment with sodium periodate cleaves the fragment into the following subfragments: ##STR9## Alternatively, the 1,2-diol group may be replaced with linker groups that contain a hydroxylamine-sensitive linkage, a base-sensitive sulfone linkage, or a thiol-sensitive disulfide linkage. Such linker groups may be derived from conventional cross-linking agents that are used to conjugate proteins to other entities. Likewise, protecting groups other than DMT may be used.

Hybridization Assays.

In nucleic acid hybridization assays, the multimer of the invention is bound to the analyte nucleic acid or to a single-stranded oligonucleotide bound to the analyte. Since the multimer includes a relatively large number of oligonucleotide units that are available for binding with the labeled oligonucleotide, many more label groups may be bound to the analyte than in prior procedures. The large number of label groups decreases the threshold level of detectable analyte, in some instances to the subattomole (10-18 mole) level.

The multimers may be used in essentially any of the known nucleic acid hybridization formats, such as those in which the analyte is bound directly to a solid phase or sandwich hybridizations in which the analyte is bound to an oligonucleotide that is in turn bound to a solid phase. It is particularly useful in the solution phase sandwich hybridization assay format described in copending application Ser. No. 807,624, filed 11 Dec. 1985.

In a solution-phase sandwich hybridization assay with a capture step the amplifier is used as follows. Single-stranded analyte nucleic acid is incubated under hybridization conditions with an excess of two single-stranded nucleic acid probes (or probe sets), (1) a capture probe having a first binding sequence complementary to the analyte and a second binding sequence that is complementary to a single-stranded oligonucleotide bound to a solid phase, and (2) an amplifier probe having a first binding sequence that is complementary to the analyte and a second binding sequence that is complementary to an oligonucleotide unit of the amplification multimer. By using an amplifier probe, the multimer may be designed to be a "universal" reagent and different multimers need not be made for each analyte. The resulting product is a three component nucleic acid complex of the two probes hybridized to the analyte by their first binding sequences. The second binding sequences of the probes remain as single-stranded tails as they are not complementary to the analyte. Multiple probes of each type may be used.

This complex is then added under hybridizing conditions to a solid phase having a single-stranded oligonucleotide bound to it that is complementary to the second binding sequence of the capture probe. The resulting product comprises the complex bound to the solid phase via the duplex formed by the oligonucleotide bound to the solid phase and the second binding sequence of the capture probe. The solid phase with bound complex is then separated from unbound materials.

The multimer is then added to the solid phase-analyte-probe complex under hybridization conditions to permit the multimer to hybridize to the available second binding sequences of the amplifier probe of the complex. The resulting solid phase complex is then separated from any unbound multimer by washing. The labeled oligonucleotide is then added under conditions which permit it to hybridize to the complementary oligonucleotide units of the multimer. The resulting solid phase labeled nucleic acid complex is then separated from excess labeled oligonucleotide, by washing to remove unbound labeled oligonucleotide, and read.

The amplification may be multiplied by the use of more than one multimer in the assay. In such instances a first multimer is designed to function as or to bind to the amplifier probe and to a second multimer and the second multimer is designed to bind to the first multimer and to the labeled oligonucleotide. Any number of multimers may be bound in series in this manner to achieve even greater amplification.

The analyte nucleic acids may be from a variety of sources, e.g., biological fluids or solids, food stuffs, environmental materials, etc., and may be prepared for the hybridization analysis by a variety of means, e.g., proteinase K/SDS, chaotropic salts, etc. Also, it may be of advantage to decrease the average size of the analyte nucleic acids by enzymatic, physical or chemical means, e.g., restriction enzymes, sonication, chemical degradation (e.g., metal ions), etc. The fragments may be as small as 0.1 kb, usually being at least about 0.5 kb and may be 1 kb or higher. The analyte sequence is provided in single-stranded form for analysis. Where the sequence is naturally present in single-stranded form, denaturation will not be required. However, where the sequence is present in double-stranded form, the sequence will be denatured. Denaturation can be carried out by various techniques, such as alkali, generally from about 0.05 to 0.2M hydroxide, formamide, salts, heat, or combinations thereof.

The first binding sequences of the capture probe and amplifier probe that are complementary to the analyte sequence will each be of at least 15 nucleotides (nt), usually at least 25 nt, and not more than about 5 kb, usually not more than about 1 kb, preferably not more than about 100 nt. They will typically be approximately 30 nt. They will normally be chosen to bind to different sequences of the analyte. The first binding sequences may be selected based on a variety of considerations. Depending upon the nature of the analyte, one may be interested in a consensus sequence, a sequence associated with polymorphisms, a particular phenotype or genotype, a particular strain, or the like.

By appropriate selection of the first binding sequences of the amplifier and capture probes they may be used to identify a specific nucleic acid molecule that includes a particular gene or other sequence that is present as part of different nucleic acid molecules. In order to discriminate the nucleic acid molecule of interest from other molecules that also contain the given sequence, one of the probes is made complementary to the given sequence while the other is made complementary to another sequence of the molecule which other sequence is unique to that molecule (i.e., is not present in the other molecules that contain the given sequence). Such a technique is exemplified by the TEM-1NH assay described in the examples, infra.

The second binding sequences of the capture probe and amplifier probe are selected to be complementary, respectively, to the oligonucleotide attached to the solid phase and to an oligonucleotide unit of the multimer and so as to not be encountered by endogenous sequences in the sample/analyte. The second binding sequence may be contiguous to the first binding sequence or be spaced therefrom by an intermediate noncomplementary sequence. The probes may include other noncomplementary sequences if desired. These noncomplementary sequences must not hinder the binding of the binding sequences or cause nonspecific binding to occur.

The capture probe and amplifier probe may be prepared by oligonucleotide synthesis procedures or by cloning, preferably the former.

It will be appreciated that the binding sequences need not have perfect complementarity to provide homoduplexes. In many situations, heteroduplexes will suffice where fewer than about 10% of the bases are mismatches, ignoring loops of five or more nucleotides. Accordingly, as used herein the term "complementary" intends a degree of complementarity sufficient to provide a stable duplex structure.

The solid phase that is used in the assay may be particulate or be the solid wall surface of any of a variety of containers, e.g., centrifugal tubes, columns, microtiter plate wells, filters, tubing, etc. When particles are used, they will preferably be of a size in the range of about 0.4 to 200 microns, more usually from about 0.8 to 4.0 microns. The particles may be any convenient material, such as latex, or glass. Microtiter plates are a preferred solid surface. The oligonucleotide that is complementary to the second binding sequence of the capture probe may be stably attached to the solid surface through functional groups by known procedures.

It will be appreciated that one can replace the second binding sequence of the capture probe and the oligonucleotide attached to the solid phase with an appropriate ligand-receptor pair that will form a stable bond joining the solid phase to the first binding sequence of the capture probe. Examples of such pairs are biotin/avidin, thyroxine/thyroxine-binding globulin, antigen/antibody, carbohydrate/lectin, and the like.

The labeled oligonucleotide will include a sequence complementary to the second oligonucleotide units of the multimer. The labeled oligonucleotide will include one or mole molecules ("labels"), which directly or indirectly provide for a detectable signal. The labels may be bound to individual members of the complementary sequence or may be present as a terminal member or terminal tail having a plurality of labels. Various means for providing labels bound to the sequence have been reported in the literature. See, for example, Leary et al., Proc Natl Acad Sci USA (1983) 80:4045; Renz and Kurz, Nucl Acids Res (1984) 12:3435; Richardson and Gumport, Nucl Acids Res (1983) 11:6167; Smith et al., Nucl Acids Res (1985) 13:2399; Meinkoth and Wahl, Anal Biochem (1984) 138:267. The labels may be bound either covalently or non-covalently to the complementary sequence. Labels which may be employed include radionuclides, fluorescers, chemiluminescers, dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, enzyme subunits, metal ions, and the like. Illustrative specific labels include fluorescein, rhodamine, Texas red, phycoerythrin, umbelliferone, luminol, NADPH, α-β-galactosidase, horseradish peroxidase, etc.

The labeled oligonucleotide can be conveniently prepared by chemical synthesis such as that described in commonly owned copending application Ser. No. 945,876. By providing for a terminal group which has a convenient functionality, various labels may be joined through the functionality. Thus, one can provide for a carboxy, thiol, amine, hydrazine or other functionality to which the various labels may be joined without detrimentally affecting duplex formation with the sequence. As already indicated, one can have a molecule with a plurality of labels joined to the sequence complementary to the labeling sequence. Alternatively, one may have a ligand bound to the labeling sequence and use a labeled receptor for binding to the ligand to provide the labeled analyte complex.

The ratio of capture probe and amplifier probe to anticipated moles of analyte will each be at least stoichiometric and preferably in excess. This ratio is preferably at least about 1.5:1, and more preferably at least 2:1. It will normally be in the range of 2:1 to 10,000:1. Concentrations of each of the probes will generally range from about 10-9 to 10-6 M, with sample nucleic acid concentrations varying from 10-21 to 10-12 M. The hybridization steps of the assay will generally take from about 10 minutes to 2 hours, frequently being completed in about 1 hour. Hybridization can be carried out at a mildly elevated temperature, generally in the range from about 20° C. to 80° C., more usually from about 35° C. to 70° C., particularly 65° C.

The hybridization reaction is usually done in an aqueous medium, particularly a buffered aqueous medium, which may include various additives. Additives which may be employed include low concentrations of detergent (0.1 to 1%), salts, e.g., sodium citrate (0.017 to 0.170M), Ficoll, polyvinylpyrrolidine, carrier nucleic acids, carrier proteins, etc. Nonaqueous solvents may be added to the aqueous medium, such as dimethylformamide, dimethylsulfoxide, alcohols, and formamide. These other solvents will be present in amounts ranging from 2 to 50%.

The stringency of the hybridization medium may be controlled by temperature, salt concentration, solvent system, and the like. Thus, depending upon the length and nature of the sequence of interest, the stringency will be varied.

The procedure used in the separation steps of the assay will vary depending upon the nature of the solid phase. For particles, centrifugation or filtration will provide for separation of the particles, discarding the supernatant or isolating the supernatant. Where the particles are assayed, the particles will be washed thoroughly, usually from one to five times, with an appropriate buffered medium, e.g., PBS containing a detergent such as SDS. When the separation means is a wall or support, the supernatant may be isolated or discarded and the wall washed in the same manner as indicated for the particles.

Depending upon the nature of the label, various techniques can be employed for detecting the presence of the label. For fluorescers, a large number of different fluorometers are available. For chemiluminescers, luminometers or films are available. With enzymes, a fluorescent, chemiluminiscent, or colored product can be provided and determined fluorometrically, luminometrically, spectrophotometrically or visually. The various labels which have been employed in immunoassays and the techniques applicable to immunoassays can be employed with the subject assays.

In a hybridization assay in which the analyte nucleic acid is bound directly to a solid phase, such as a "dot blot" assay, the multimer is hybridized directly to the bound analyte. In these instances, the first oligonucleotide unit(s) of the multimer is complementary to a sequence of the analyte and the second oligonucleotide units are complementary to a labeled oligonucleotide. Unbound multimer is removed from the solid phase and the labeled oligonucleotide is then hybridized to the bound analyte-multimer complex. Excess labeled oligomer is removed and the labeled, bound complex is read.

The multimers may also be used in other assays such as direct, indirect, and sandwich immunoassays. In these instances the reagent that plays the role of the labeled antibody or other ligand that is bound directly or indirectly to the analyte has an oligonucleotide that is complementary to the first oligonucleotide unit of the multimer bound to it rather than a label. For instance, in a sandwich immunoassay for an antigen analyte, the analyte sample is incubated with a solid phase to which is bound a first antibody to the antigen. Unbound sample is removed from the solid phase and a second antibody to the antigen and which an oligonucleotide complementary to a unit of the multimer is bound is reacted with the bound complex to form a three-membered complex. Following removal of excess second antibody the multimer is then hybridized to the complex via the oligonucleotide bound to the second antibody. Excess multimer is removed and a labeled oligonucleotide is hybridized to the other oligonucleotide units of the multimer. After removal of excess labeled oligonucleotide, the complex is read.

Kits for carrying out amplified nucleic acid hybridization assays according to the invention will comprise in packaged combination the following reagents: the multimer; an appropriate labeled oligonucleotide; a solid phase that is capable of binding to the analyte; optionally a capture probe if the assay format is one in which the analyte is bound to the solid phase through an intermediate oligonucleotide or other ligand; and optionally an amplifier probe if the assay format is one in which the multimer is not hybridized directly to the analyte. These reagents will typically be in separate containers in the kit. The kit may also include a denaturation reagent for denaturing the analyte, hybridization buffers, wash solutions, enzyme substrates, negative and positive controls and written instructions for carrying out the assay.

The following examples of the invention are offered by way of illustration and not by way of limitation.

Examples

1. Enzymatic Preparation of Linear Multimer

A linear multimer of an 18-mer that is complementary to amplifier probes (see 3.F. below) was prepared according to the scheme depicted in FIG. 1.

Two 18-mers, LLA-1 and LLA-2, were synthesized by an automated phosphoramidite method as described in Warner et al., DNA (1984) 3:401. Purification was carried out according to Sanchez-Pescador and Urdea, DNA (1984) 3:339. Phosphorylation of the 5' end of the LLA-2 was carried out by the chemical phosphorylation procedure described in Example 1 of commonly owned copending U.S. application Ser. No. 087,158, filed 18 Aug. 1987, the disclosure of which is incorporated herein by reference. The sequences of LLA-1 and LLA-2 were as follows. ##STR10##

The linear LLA-2 polymer was formed using T4 DNA ligase. The products of such ligations are double-stranded. Single-stranded polymer may be obtained by gel purifying the product under denaturing conditions.

One hundred thousand pmole of each sequence were added to a 1.5 ml tube and evaporated to dryness under vacuum.

The following solution was added to the dried sequences:

100 μl KBTS buffer*

100 μl 10 mM DTT

100 μl 10 mM ATP

50 μl H2 O

50 μl 1M NaCl

500 μl 30% PEG.

*10× (50 mM Tris HCl, pH 7.6, 10 mM MgCl2, 1 mg/ml spermidine)

The tube was vortexed and then heated to 55° C. for 30 min. The tube was then cooled to room temperature and the following solution was added

6.7 μl T4 DNA Ligase (New England Nuclear 15 U/μl)

18.8 μl 5× Ligase Dilution Buffer (NEN) 74.5 μl H2 O

Again the tube was vortexed and then incubated at room temperature overnight. The reaction mixture was extracted with n-butanol to a volume of 100 μl, 100 μl of 3× stop mix (25% glycerol, 0.05% bromphenol blue, 0.5% sodium dodecyl sulfate, 25 mM EDTA) was added and then heated to 100° C. for 5 min. to denature the sample. Twenty μl portions of this solution were then added to the wells of a 7% denaturing polyacrylamide gel (10 cm×10 cm×1.5 mm). The gel was run at 10 V/cm until the bromphenol blue dye was within 0.5 cm of the bottom of the gel. The products formed were made visible by placing the gel on a thin layer chromatography plate containing a UV fluorescing dye covered with Saran wrap and illuminating with a long wave UV lamp. The products absorb the UV irradiation and cast a visible shadow. Bands of increasing length were observed and polymeric products greater than twenty oligomeric units long were cut out. These products were eluted from the gel by soaking in Maxim-Gilbert buffer (0.1M Tris-HCl, pH 8, 0.5M NaCl, 5 mM EDTA).

2. Chemical Preparation of Linear and Branched Multimers

A. Preparation of Linear and Branched Multimers

Linear and branched multimers of an 18-mer that are complementary to the amplifier probes (see 3.F. below) were prepared according to the schemes depicted in FIGS. 2A and 2B.

As indicated, the schemes use oligonucleotide units having derivatized bases that are cross-linked with phenyldiisothiocyanate (DITC).

The oligonucleotide used to prepare the linear multimer had the sequence

3'-XGCACAGTCCGTATCCTGGX-5'

where X represents the N4 -(6-aminocaproyl-2-aminoethyl) derivative of cytidine.

The oligonucleotide used for the branched multimer had the sequence

5'-XTGGTCCTATGCCTGACACGTXTGGTCCTATGCCTGACACGTXT-3'

where X is as above.

The N4 -(6-aminocaproyl-2-aminoethyl) derivative of cytidine was prepared as described in commonly owned copending application Ser. No. 945,876. The oligomers were synthesized and purified as described in Example 1.

A sample of 0.2 OD260 units of either fragment was dissolved in 0.5 μl of 0.1M sodium borate, pH 9.3, to which 9.5 μl of DITC in dimethylformamide (2 mg/ml) was added. The solution was vortexed and set at room temperature overnight in the dark. After the addition of 300 μl of n-butanol and mixing, 300 μl of water was added. The mixture was vortexed and centrifuged to separate the layers. The sample was extracted several times until the aqueous phase was lowered to a volume of approximately 50 μl and then vacuumed to dryness. The polymer was then treated with 10 μl of 1M glycine, pH 9.5, for 2 hr to modify any remaining isothiocyanate groups. The mixture was loaded onto a 10 ml Sephadex G-25 column, eluted with water, collected, evaporated to dryness, taken up in 1% SDS and loaded onto a 7% polyacrylamide gel (vertical 2% agarose gels are preferred for preparation runs). The gel was run at 60 ma and then stained with ethidium bromide. Bands estimated to comprise 10-25 units of the oligomer were cut, electroeluted and precipitated.

B. Preparation of Comb-like and Bifurcated Multimers

In this section DMT=dimethoxytrityl; T=deoxythymidine; DMF=dimethylformamide; BDMS=t-butyldimethylsilyl; C=deoxycytidine; TLC=thin-layer chromatography; DMAP=N,N-dimethylaminopyridine; THF=tetrahydrofuran; DIPEA=diisopropylethylamine; LEV=levulinic ester; DCA=dichloroacetic acid; DCC=dicyclohexylcarbodiimide; DCHU=dicyclohexylurea; TEA=triethylamine; TMS=trimethylsilyl; FMOC=9-fluorenylmethoxycarbonyl.

B.1A. Synthesis of Nucleotide for Forming Comb-Like Branch Points

5-DMT-T-OH (27.3 g, 50 mmole) and imidazole (10 g, 150 mmole) were coevaporated with 200 ml DMF. The residue was dissolved in 250 ml DMF, and BDMS chloride (75 mmol) was added. The reaction mixture was stirred for 18 hr at 20° C. Methanol (50 ml) was added and after 30 min the solvents were removed in vacuo. The oily residue was dissolved in 50 ml ethyl acetate, and the organic phase extracted with 5% aqueous NaHCO3 (2×500 ml) and 80% saturated aqueous NaCl (500 ml) and finally dried over solid Na2 SO4. The solvent was removed in vacuo to give 35 g (50 mmole) 5'-DMT-3'BDMS T (100% yield). This material was used without further purification.

Triazole (25.6 g) was suspended in 400 ml of CH3 CN (at 0° C.) and POCl3 (8 ml) was added with rapid stirring. Then triethylamine (60 ml) was added dropwise over 15 min to the slurry stirred at 0° C. for 30 min. 5'-DMT-3'BDMS T (25 mmole crude) dissolved in 100 ml CH3 CN was added dropwise to the above stirred slurry at 0° C. The ice-water bath was removed and stirring continued at 20° C. for one hour. The reaction mixture was diluted with 800 ml ethyl acetate, and the organic phase was extracted with 5% NaHCO3 (2×500 ml) and 80% saturated aqueous NaCl (500 ml). After drying the organic phase over solid Na2 SO4 solvents were removed in vacuo. The resulting residue was coevaporated with toluene (400 ml) and CH3 CN (400 ml) to give 5'-DMT-3'-BDMS-5-methyl-4-triazoyl β-D-2-deoxyribofuranosyl-2(1H)-pyrimidinone as a white foam in quantitative yield. This material was used without further purification.

To a solution of 6-aminohexanol (11.7 g, 100 mmole) in 400 ml CH3 CN was added dropwise 5'-DMT-3'-BDMS-5-methyl-4-triazoyl β-D-2-deoxyribofuranosyl-2(1H)-pyrimidinone (8.7 g, 12 mmole) dissolved in 100 ml CH3 CN and the reaction mixture stirred at 20° C. The progress of the reaction was monitored by TLC (every 30 min) and when the starting material had completely disappeared (usually in 1-2 hours), the reaction mixture was diluted with 500 ml ethyl acetate, which was extracted with 5% aqueous NaHCO3 and 80% saturated aqueous NaCl as described above. After drying of the organic phase over Na2 SO4, the solvent was removed in vacuo to give 7.0 g (9.2 mmole) of product 5'-DMT-3'-BDMS-5-methyl-N4 -6-hydroxyhexyl deoxycytidine (yield 77%). This material was used without further purification.

To a solution of 5'-DMT-3'-BDMS-5-methyl-N4 -6-hydroxyhexyl deoxycytidine (7 g, 9.2 mmole) in 100 ml THF was added (CH3 COCH2 CH2 CO)2 O (50 mmole) dissolved in 100 ml THF and then 10 ml 6.5% DMAP in 2,6-lutidine/THF. The reaction mixture was left stirring for 30 min. The analysis showed that starting material had been completely consumed. The reaction mixture was diluted with 700 ml ethyl acetate which was diluted with 700 ml ethyl acetate which was extracted with 5% aqueous NaHCO3 (3×500 ml) and 80% saturated aqueous NaCl (500 ml) as described above. After drying over solid Na2 SO4, the solvent was removed and the residue coevaporated with toluene (200 ml) and CH3 CN (200 ml) to give 12.3 g of crude product.

This crude product was dissolved in 100 ml THF, and 10 ml of a 1.1M solution of tetrabutylammonium fluoride in THF was added. The progress of the reaction was monitored by TLC; it is usually over in 30 min but may take longer. When starting material had been consumed, the reaction mixture was diluted with 700 ml ethyl acetate, which was extracted with NaHCO3 and NaCl solutions, as above. Removal of the solvent afforded 8.5 g crude product 5'-DMT-5-methyl-N4 (O-levulinyl-6-oxyhexyl)-2'-deoxycytidine. This material was subjected to silica gel chromatography. The purified product was isolated by elution with 4% methanol in CH2 Cl2 to give 5.0 g of a slightly brownish foam (6.7 mmole; 73% yield).

Silica-purified 5'-DMT-5-methyl-N4 (O-levulinyl-6-oxyhexyl)-2'-deoxycytidine (7.7 mmole) was coevaporated twice with CH3 CN. The resulting dry powder was dissolved in 70 ml CH2 Cl2 containing 4.9 ml DIPEA in a flask under argon. After cooling to 0° C., 1.65 ml (8.5 mmole) N,N-diisopropylaminomethoxy chlorophosphine was added with a syringe and the mixture stirred at 0° for 30 min. After dilution with 400 ml ethyl acetate, the organic phase was washed 4 times with 400 ml 80% saturated aqueous NaCl, then dried over solid Na2 SO4 and filtered. The solvent was removed in vacuo and the resulting residue coevaporated twice with toluene to give an oil. This oil was dissolved in 30 ml toluene and added dropwise into 400 ml cold hexane (˜-20° C.). The precipitate was quickly collected by filtration and dried in vacuo for 18 hr to give 5.45 g of phosphoramidite (6.0 mmole; 78% yield).

B.1B. Synthesis of Alternative, Preferred Nucleotide for Forming Comb-Like Branch Points

To a solution of 5'-DMT-3-BDMS-5-methyl-N4 -6-hydroxyhexyl deoxycytidine (34 g, 50 mmole) prepared as described above in 200 ml CH2 Cl2 was added 1.5 g N,N-dimethylaminopyridine and 25 ml triethylamine. To this solution at 0° C. was added dropwise DMT-Cl (75 mmole, 25.5 g) dissolved in CH2 Cl2 (100 ml). The reaction mixture was left stirring for 1 hour. The analysis showed that starting material had been completely consumed. Then 50 ml of methanol was added. After 30 min the reaction mixture was diluted with 800 ml ethyl acetate which was extracted with 5% NaHCO3 (2×500 ml) and 80% saturated aqueous NaCl (500 ml) described above. After drying over solid Na2 SO4 the solvent was removed in vacuo and the residue coevaporated with toluene (200 ml) and CH3 CH (200 ml).

This crude product was dissolved in 200 ml THF, and 200 ml of a 1.1M solution of tetrabutylammonium fluoride in THF was added. The progress of the reaction was monitored by TLC; it is usually over in 30 min but may take longer. When starting material had been consumed, the reaction mixture was diluted with 700 ml ethyl acetate, which was extracted with NaHCO3 and NaCl solutions, as above. Removal of the solvent afforded 36 g crude product, 5'-DMT-5-methyl-N4 (O-DMT-6-oxyhexyl)deoxycytidine. This material was subjected to silica gel chromatography. The purified product was isolated by elution with 2-4% methanol in CH2 Cl2 to give 32.7 g of pure product (34 mmole; yield based on 5'-DMT-T-OH: 69%).

Silica-purified 5'-DMT-5-methyl-N4 (O-DMT-6-oxyhexyl)-2'-deoxycytidine (34 mmole) was coevaporated twice with CH3 CN. The resulting dry powder was dissolved in 100 ml CH2 Cl2 containing 7.5 ml DIPEA in a flask under argon. After cooling to 0° C., 7.37 ml (38 mmole) N,N-diisopropylaminomethoxy chlorophosphine was added with a syringe and the mixture stirred at 0° for 30 min. After dilution with 800 ml ethyl acetate, the organic phase was washed 4 times with 800 ml 80% saturated aqueous NaCl, then dried over solid Na2 SO4 and filtered. The solvent was removed in vacuo and the resulting residue coevaporated twice with toluene to give an oil. This oil was dissolved in 80 ml toluene and added dropwise into 700 ml cold hexane (˜-20° C.). The precipitate was quickly collected by filtration and dried in vacuo for 18 hr to give 31.8 g of phosphoramidite (28.7 mmole; 84% yield).

5'-DMT-T-OH (16.4, 30 mmole) was dissolved in dry 200 ml CH3 CN and 1-(TMS)imidazole (14.6 ml, 100 mmole) was added. After 60 min the solvents were removed in vacuo. The oily residue was dissolved in 700 ml ethyl acetate, and the organic phase extracted with 5% aqueous NaHCO3 (2×500 ml) and 80% saturated aqueous NaCl (500 ml) and finally dried over solid Na2 SO4. The solvent was removed in vacuo to give 30 mmole 5'-DMT-3'-TMS-T (100% yield). This material was used without further purification.

Triazole (37.8 g) was suspended in 450 ml of CH3 CN (at 0° C.) and POCl3 (12 ml) was added with rapid stirring. Then triethylamine (90 ml) was added dropwise over 15 min to the slurry stirred at 0° C. for 30 min. 5'-DMT-3'-TMS-T (30 mmole crude) dissolved in 100 ml CH3 CN was added dropwise to the above stirred slurry at 0° C. The ice-water bath was removed and stirring continued at 20° C. for one hour. The reaction mixture was diluted with 800 ml ethyl acetate, and the organic phase was extracted with 5% NaHCO3 (2×500 ml) and 80% saturated aqueous NaCl (500 ml). After drying the organic phase over solid Na2 SO4 solvents were removed in Vacuo. The resulting residue was coevaporated with toluene (400 ml) and CH3 CN (400 ml) to give 5'-DMT-3'-TMS-5-methyl-4-triazoyl β-D-2- deoxyribofuranosyl-2(1H)-pyrimidinone as a white foam in quantitative yield. This material was used without further purification.

To a solution of 6-aminohexanol (23 g, 200 mmole) in 400 ml CH3 CN was added dropwise 5'-DMT-3'-TMS-5-methyl-4-triazoyl β-D-2-deoxyribofuranosyl-2(1H)pyrimidinone (20 g, 30 mmole) dissolved in 100 ml CH3 CN and the reaction mixture stirred at 20° C. The progress of the reaction was monitored by TLC (every 30 min) and when the starting material had completely disappeared (usually in 1-2 hours), the reaction mixture was diluted with 800 ml ethyl acetate, which was extracted with 5% aqueous NaHCO3 and 80% saturated aqueous NaCl as described above. After drying of the organic phase over Na2 SO4, the solvent was removed in vacuo to give 20.3 g (˜30 mole) of product 5'-DMT-3'-TMS-5-methyl-N4 -6-hydroxyhexyl deoxycytidine. This material was used without further purification.

To a solution of 5'-DMT-3'-TMS-5-methyl-N4 (6-hydroxyhexyl)deoxycytidine in 250 ml methanol was added 25 ml concentrated aqueous NH4 OH and the reaction mixture left stirring in a closed round-bottom flask to 1 hour. The solvent was then removed in vacuo and coevaporated with 1×200 ml ethanol, 1×100 ml toluene and 1×100 ml CH3 CN to give 5'-DMT-5-methyl-N4 (6-hydroxylhexyl)deoxycytidine in quantitative yield. This material was used without further purification. This material was dissolved in 200 ml CH2 Cl2 and 4 ml of pyridine was added followed by dropwise addition of FMOC-Cl (7.8 g, 30 mole) dissolved in CH2 Cl2 (50 ml). The reaction mixture was left stirring for 30 min. The analysis showed that starting material had been completely consumed. The reaction mixture was diluted with 500 ml ethyl acetate which was extracted with 5% aqueous NaHCO3 (3×500 ml) and 80% saturated aqueous NaCl (500 ml) as described above. After drying over solid Na2 SO4, the solvent was removed and the residue coevaporated with toluene (200 ml) and CH3 CN (200 ml) to give 23.7 g of crude product. This crude product was subjected to silica gel chromatography. The purified product eluted with about 4% methanol in CH2 Cl to give 13.3 g (15.3 mmole) of pure 5'-DMT-5-methyl-N4 (O-FMOC-6-oxyhexyl)deoxycytidine (50% yield based on 5'-DMT-TOH).

Silica-purified 5'-DMT-5-methyl-N4 (O-FMOC-6-oxyhexyl)-2'-deoxycytidine (15.3 mmole) was coevaporated twice with CH3 CN. The resulting dry powder was dissolved in 60 ml CH2 Cl2 containing 4.1 ml DIPEA in a flask under argon. After cooling to 0° C., 3.19 ml (16.5 mmole) N N-diisopropylaminomethoxy chlorophosphine was added with a syringe and the mixture stirred at 0° for 30 min. After dilution with 400 ml ethyl acetate, the organic phase was washed 4 times with 400 ml 80% saturated aqueous NaCl, then dried over solid Na2 SO4 and filtered. The solvent was removed in vacuo and the resulting residue coevaporated twice with toluene to give an oil. This oil was dissolved in 50 ml toluene and added dropwise into 400 ml cold hexane (˜-20° C.). The precipitate was quickly collected by filtration and dried in vacuo for 18 hr to give 12.15 g of phosphoramidite (11.8 mmole; 77% yield). Removal of O-FMOC group during solid phase synthesis: t-butylamine/pyridine (1:10 v/v) for 1 hour at 20°. Removal of O-levulinyl group: 0.5M hydrazine hydrate in pyridine/glacial acetic acid (4:1 v/v) 15 minutes at 20° C.

B.2. Synthesis of a Multifunctional Phosphoramidite for Forming Bifurcated Branch Points

Glycerol (10 mmole) was dried by coevaporation with pyridine. The resulting oil was dissolved in 50 ml pyridine and DMT-Cl (6.8 g, 20 mmole) was added, and the reaction mixture was stirred at 20° C. for 18 hr. After addition of methanol (10 ml), the solvent was removed on a rotary evaporator. The resulting oil was dissolved in 250 ml ethyl acetate and the organic phase was washed with 5% aqueous NaHCO3 (2×250 ml), 80% saturated aqueous NaCl (1×250 ml) and then dried over solid Na2 SO4. The solvent was removed in vacuo and the residue coevaporated with 100 ml toluene and 100 ml CH3 CN. The product was isolated by silica gel chromatography to give 2.5 g (3.6 mmole) 0,0-bis DMT glycerol (35% yield). Product elutes with 0-1% MeOH.

The bis-DMT glycerol (2.3 mmole) was dissolved in CH2 Cl2 (10 ml) containing DIPEA (0.8 ml) under argon, and N,N-diisopropylamino-2-cyanoethoxy-chlorophosphine (1 ml) was added by syringe. After 30 minutes the mixture was diluted with ethyl acetate (200 ml) and the organic phase washed with 200 ml 80% saturated aqueous NaCl. After drying over solid Na2 SO4, the solvent was removed in vacuo, and the residue coevaporated with 100 ml toluene and 100 ml dry CH3 CN to give 2.15 g (2.3 mmole; 100% yield) of bis-DMT glycerol phosphoramidite. The product was dispensed with dry CH3 CN into small septum-capped vials and after removal of the solvent stored at -20° C. under argon.

B.3. Synthesis of Periodate-Cleavable Linker Phosphoramidite

O,O-Dibenzoyl tartaric acid monohydrate (18.8 g, 50 mmole) was dissolved in 250 ml CH3 CN and the solvent was removed in vacuo. This process was repeated. The resulting oil was dissolved in 250 ml THF and DCC (10.6 g, 50 mmole) dissolved in 50 ml THF was added. A precipitate started forming in a few minutes. After stirring for 18 hr at 20° C. the reaction mixture was filtered, and the precipitate washed with THF. The precipitate was dried in high vacuum to give 10.8 g (50 mmole) DCHU. To the combined filtrate was added 2-(N-methyl)aminoethanol (4.0 ml, 50 mmole) and the reaction mixture was stirred for 1 hr at 20° C. DCC (10.6 g, 50 mmole) in 50 ml THF was then added. A small precipitate formed. After about 1 hr, 2-(N-methyl)aminoethanol (4.0 ml, 50 mmole) was added and the reaction mixture stirred for 18 hours at 20° C.

The formed precipitate was filtered off and washed with THF. The dried precipitate of DCHU weighed 10.8 g. The combined filtrate was evaporated to an oil. Chromatography on silica afforded 8 g (17 mmole) of O,O-dibenzoyl tartaric di(N-methyl-2-hydroxyethyl)amide (this product elutes with 6% MeOH/CH2 Cl2).

To the amide product (8.6 mmole) in 50 ml CH2 Cl2 containing DMAP (0.11 g) and TEA (2.4 ml) was added dropwise, DMT-Cl (8.6 mmole) dissolved in 50 ml CH2 Cl2. After addition of DMT-Cl the reaction mixture was stirred for 1 hr at 20° C., then the solvent was removed by evaporation. The residue was dissolved in 600 ml ethyl acetate and the organic phase washed with 400 ml 5% NaHCO3 and 400 ml 80% saturated aqueous NaCl. The organic phase was dried over solid Na2 SO4. After 30 min the Na2 SO4 was filtered off, and the supernatant was concentrated to an oil, then coevaporated with toluene and CH3 CN. The crude material was subjected to silica gel chromatography using n-butanol/CH2 Cl2 for elution. The pure mono-DMT product eluted with 2-3% n-butanol/CH2 Cl2 to give 1.53 g (2 mmole) of O,O-dibenzoyl tartaric 2-(O-dimethoxytrityl)hydroxyethyl-N,N-dimethyl, N-methyl-2-hydroxyethyldiamide.

This material was dissolved in 20 ml CH2 Cl2 containing DIPEA (3 mmole). After cooling to 10° C., 2.2 mmole methoxy-N,N-diisopropylaminochlorophosphine was added under argon. After 15 min, ethyl acetate was added, and the organic phase washed with 80% saturated aqueous NaCl, dried over solid Na2 SO4 and evaporated to dryness. After coevaporation with toluene and dry CH3 CN, the phosphoramidite residue was dissolved in 10 ml dry CH3 CN. This solution was aliquoted into 19 dry Weaton vials and the solvent removed in vacuo. The vials were closed with septum screw caps and stored at -20° C.

This phosphoramidite may be coupled to oligonucleotides using standard DNA synthesis techniques and equipment. After deprotection the resulting linker-containing DNA may be cleaved at the 1,2-diol site as described above.

B.4. Synthesis of a Four-Site Bifurcated Amplification Multimer

For synthesis of branched fragments, a 2000 A control pore glass (CPG) support (30 mg of 7.3 μmole of nucleoside/g) was used. The CPG support was synthesized as described in the Commonly owned copending U.S. application Ser. No. 087,158, filed 18 Aug. 1987. An automated methyl phosphoramidite coupling procedure was employed for DNA synthesis as above, except that during the addition of the branched oligonucleotide segments 2.5% (v/v) DCA in toluene (instead of CH2 Cl2) was used for detritylation.

Fragment LLA-2 (GACACGGGTCCTATGCCT; see above) was synthesized on the CPG, then removed from the automated synthesizer and placed into a sintered glass funnel. Manual phosphoramidite couplings were then performed as described (Urdea, M.S., Methods in Enzymol (1987) 146:22-41). A 100 μmole aliquot of the DMT2 -glycerol phosphoramidite (2-cyanoethyl form) and 250 μmoles of tetrazole were added to the 5'-deprotected fragment and incubated for 15 min. This process was then repeated. Two T methyl phosphoramidites were then added manually and an additional glycerol phosphate was added. The CPG was then placed back on the automated synthesizer and the fragment GATGTGGTTGTCGTACTTTT was synthesized off of each branch. The standard deprotection and purification as above was then employed.

B.5. Synthesis of a Four-Site Comb Amplification Multimer

Using the methods described above, the fragment TTOTTOTTOTTGACACGGGTCCTATGCCT (O=5'-DMT-N4 -[LevO(CH2)6 ]-5-Me cytidine methyl phosphoramidite) was synthesized. The fragment was then removed from the machine and treated for 1 hr at room temperature with 0.5M hydrazine monohydrate in 8:2 (v/v) pyridine/concentrated acetic acid. The CPG was then washed with pyridine, then 1:1:2 (v/v/v) H2 O/lutidine/THF. The support was then placed back on the automated synthesizer and the fragment was synthesized off of each O in the above formula. The standard deprotection and purification as above was then employed. Note that one copy of the labeled probe (LLA-2) binding fragment is at the 5'-end of the multimer and three copies of the fragment are at the O residues.

3. Sandwich Hybridization Assay for Hepatitis B Virus (HBV) DNA Using Multimer

FIG. 4 schematically depicts the assay procedure.

A. Standard Analyte HBV DNA

The plasmid pHE63 composed of the entire 3.2 kb HBV genome cloned into the EcoRI site of plasmid pBR325 linearized with EcoRI and diluted into normal human serum was used as standard analyte. The analyte is designated 11 in FIG. 4.

B. Solid Phase Oligonucleotide Complex (C in FIG. 4)

A 21 base oligomer, 5'-XCACCACTTTCTCCAAAGAAG-3', where X is as defined above, was synthesized as described in Example 1 and biotinylated using N-hydroxysuccinimdyl biotin in 0.1M sodium phosphate, pH 7.5. A 5 μl aliquot of this biotinylated fragment (800 pmoles) was added to a 1.5 ml Eppendorf tube containing 500 μl of 0.25% (w/v) 2.8 micron avidin polystyrene beads in 1× PBS. After a 1 h incubation at 37° C., the beads were washed 3 times with 500 μl of 0.1% SDS, 4× SSC by centrifugation then resuspended and stored in the same solution until used.

C. Labeled Oligomer (E in FIG. 4)

An 18 base oligomer, 5'-XGGTCCTAGCCTGACAGC-3', where X is defined as above, was synthesized, modified with DITC in 95:5 (v/v) dimethylformamide: 0.1M sodium borate, pH 9.3, extracted with n-butanol, and combined with horseradish peroxidase (HRP).

D. Capture Probes (A in FIG. 4)

A set of 12 single-stranded oligomers each having a varying 30 base long portion complementary to a specific sequence of the HBV genome and a constant 20 base long 3'-portion complementary to the oligonucleotide bound to the solid phase was synthesized by the procedures described in Example 1.

E. Amplifier Probes (B in FIG. 4)

A set of 36 single-stranded oligomers each consisting of a varying 30 base long portion complementary to a specific sequence of the HBV genome and a constant 20 base long 3'-portion complementary to the multimer (D in FIG. 4) were synthesized by the procedures described in Example 1.

Both the capture and amplifier probes were designed for the constant ds region of the HBV virus.

F. Bead Assay Procedure

10 l samples of analyte were placed in 1.5 ml Eppendorf tubes and treated with 12.5 μl of proteinase K/SDS (Gene (1987) 61:254) at 37° C. for 30 min. To each sample, 5μl of 1M NaOH containing 50 fmoles each of the 48 HBV oligonucleotide probes (12 capture probes and 36 amplifier probes) were added and the tubes were heated to 100° C. for 10 min. The samples were set on ice for 5 min, microfuged for 10 sec and neutralized with 0.38M acetic acid, 12.3× SSC (final 4× SSC). Annealing of the probes to the analyte was conducted at 55° C. for 1 h. Subsequently, 25 μl of the capture beads were added and the solution was left at 55° C. for an additional 15 min. Two washes were performed by adding 500 μl of wash solution (0.1% SDS, 4× SSC), vortexing, centrifuging for 1 min and decanting. To each tube, 20 μl containing 50 fmoles of multimer (D in FIG. 4 ) in HM buffer (0.1% SDS, 4× SSC, 1 mg/ml sonicated salmon sperm DNA, 1 mg/ml poly-A, 10 mg/ml BSA) was added. After vortexing, the tubes were left at 55° C. for 15 min and washed twice as above. Labeling was conducted with 20 μl containing 250 fmoles of probe Type E in HM for 1 h at 37° C. After three washes as above, the beads were thoroughly drained by inversion onto Kimwipes, treated with the appropriate substrate and measured as described below. The total time required for the analysis from addition of the proteinase K/SDS solution to readout was 3 h 50 min in the chemiluminescent format.

The enhanced chemiluminescence method for HRP detection reported by Matthews et al., Anal Biochem (1985) 151:205-209, was employed. Beads were taken up in 15 μl of chemiluminescent substrate solution (luminol with p-hydroxycinnamic acid) and then transferred to 8×50 mm Evergreen polypropylene tubes containing 5 μl of 4 mM H2 O2. After 30 sec, tubes were read on a Turner TD-20e luminometer (delay, 10 sec; integration, 20 sec; smoothing, 20 sec). Output was given as the full integral of the light produced during the reaction.

To each tube, a 100 μl aliquot of a fresh o-phenylenediamine solution (OPD; in tablet form from Sigma Chemicals; 50 mg dissolved in 5 ml of 50 mM sodium citrate, pH 5.1, containing 3 μl of 30% H2 O2) was added. After 20 min at 37° C., 50 μl of 4N H2 SO4 was added to quench the reaction. The beads were then pelleted by centrifugation and the supernatant was transferred to a microtiter dish well. The dish was then read on a Biotek EL310 plate reader set at 490 nm. Longer incubations did not improve the signal to noise ratios.

G. Microtiter Dish Assay Procedure

A microtiter dish assay procedure was employed. Microtiter dishes were prepared as follows. Two types of microtiter dish wells were prepared: (1) N wells for sample work-up and negative controls, and (2) S wells for capture of the probe-analyte complex from samples and positive controls.

N wells were produced as follows: 300 μl of HM buffer was added to Immulon II Remov-a-wells (Dynatech Inc.). The well strips were covered and left standing at room temperature for 1 hour. The HM buffer was removed by aspiration and the wells were washed 3 times with 400 μl of 1× PBS. The strips were covered with plastic wrap and stored at 4° C. until used. Alternatively, wells were coated with poly-phenylalanyl-lysine then with HM buffer, as below.

S wells were prepared from the Immulon II strips as follows. To each well, 200 μl of a 200 μg/ml solution of poly-phenylalanyl-lysine (Sigma Chemical Inc.) in water. The covered strips were left at room temperature for 30 min to 2 hr, then washed as above. A 10 OD260 sample of the oligonucleotide of 3B above in 60 μl of 1× PBS was treated with 140 μl of DMF containing 10 mg of ethylene glycolbis(succinimidylsuccinate) (Pierce Chemicals Inc.). The mixture was vortexed and incubated in the dark at room temperature. After 15 min, the solution was passed over a Sephadex G-25 column (PD-10 from Pharmacia), previously equilibrated with 30 ml of 1× PBS. The void volume of the column was diluted to a final volume of 35 ml with 1× PBS. To each well, a 50 μl aliquot of the capture probe solution was added. After covering with plastic wrap, the wells were incubated at room temperature in the dark for 30 min to overnight. The wells were washed with 1× PBS, then coated with H buffer, washed, and stored as above.

Label oligonucleotides were derivatized with alkaline phosphatase (AP) as follows. Calf intestinal AP (3 mg in buffer; immunoassay grade, Boehringer-Mannheim) was placed in a Centricon 30 Microconcentrator. Approximately 2 ml of 0.1M sodium borate, pH 9.5, was then added and the device was spun at 3500 rpm until a final volume of 40 μl was obtained. The alkylamino oligonucleotide (Section 3C) was then activated with DITC, extracted with butanol, and combined with the protein as described for the HRP probe. PAGE, elution (with 0.1M Tris, pH 7.5, 0.1M NaCl, 10 mM MgCl2, 0.1 mM ZnCl2), and concentration as described for the HRP conjugates were employed. The final product was stored at 4° C.

For duplicate analyses, 20 μl of each sample was placed into 2N wells, then treated with 25 μl of proteinase K/SDS solution. The wells were covered with a Linbro-Titertek microtiter plate sealer, gently agitated, and incubated at 65° C. for 30 min in a water bath. The capture and amplifier probe sets in 1M NaOH were added in 10 μl to each well. After sealing, the samples were incubated for 10-30 min at 65° C. to 72° C. as above. The solutions were neutralized with 26 μl 10.38M acetic acid (or 0.76M 3-[N-Morpholino]propane sulfonic acid (MOPS), free acid), 12.3× SSC, then incubated for an additional 15-30 min covered at 65° C. From each N well, 40 μl of sample was transferred to a new S well containing the solid supported capture probe. The wells were sealed and set at 65° C. for 1-2 hours. Each well was then washed-2 times by aspiration with 0.1% SDS, 0.1× SSC. A solution of amplification multimer (for N. gonorrhoeae, penicillin-resistant N. gonorrhoeae, tetracycline resistant N. gonorrhoeae and Chlamydia tests; a five-site comb structure (section 2.B.5) was employed) in HM buffer was then added and the samples set sealed in a 55° C. water bath for 15 min to 1 hour. After washing as above, 20 μl of the enzyme-labeled probe in HM buffer was added. Incubation for the HRP probe was carried out for 15 min at 42° C., while the alkaline phosphatase probe was used at 55° C. for 15 min. After washing as above, the appropriate detection reagents were added.

For HRP, the enhanced luminol reagent (see 3F) was used as above.

For AP detection, an enzyme-triggered dioxetane (Schaap et al., Tet Lett (1987) 28:1159-1162 and EPA Publication No. 0254051), obtained from Lumigen Inc., was employed. The detection procedure was as follows. For the labeling step 20 μl MM buffer with the AP probe was added to each well and the wells were incubated at 55° C. for 15 min. The supernatant was removed and the wells were washed 2× with 380 μl of 0.1× SSC-0.1% SDS. The wells were then washed 2× with 380 μl of 0.1× SSC to remove any remaining SDS. 20 μl of 3.3×10-4 M dioxetane in CTAB buffer was added to each well. The wells were tapped lightly so that the reagent would fall to the bottom and gently swirled to distribute the reagent evenly over the bottom. The wells were covered with the microtiter plate sealer and incubated in a 37° C. oven for one hour. The wells are then read with a luminometer.

Results

A. Tests on Standard Analyte

The above described assay was carried out on samples containing known amounts of the standard analyte HBV DNA using the multimers of Examples 1-2A. For comparison purposes a three piece assay (bound analyte; oligonucleotide complementary to both analyte and labeled probe; and HRP-labeled probe) was carried out. The comparison assay was assigned a gain value of 1. Gain is the ratio of signal obtained in an amplified assay to signal obtained in an unamplified three piece assay.

The results of these assays are reported in the table below. S/N=signal-to-background ratio.

                                  TABLE 1__________________________________________________________________________AMPLIFIER ASSAY TYPE             GAIN                 SIGNAL BACKGROUND                                 S/N__________________________________________________________________________Enzymatically     HBV Serum             29  56.2 ± 24.4                         12.9 ± 4.73                                 4.4Ligated Multimer     Assay       @ 10 amole(Ex. 1)Chemically Cross-     HBV Serum             25  617 ± 116                        432 ± 53                                 1.4linked Linear     Assay       @ 50 amoleMultimer (Ex. 2)Chemically Cross-     HBV Serum             102 168 ± 31                        17 ± 2                                 9.9linked Branched     Assay       @ 10 amoleMultimer (Ex. 2)HRP Probe Without     3 Piece 1   32.9 ± 5.7                        18.2 ± 1.5                                 1.8Amplifier Assay       @ 100 amole__________________________________________________________________________

B. Tests on Authentic HBV DNA Samples

Authentic HBV DNA samples were identified as follows.

A dot blot screening was conducted for the presence of HBV DNA in 49 HBV surface antigen positive samples using the protein-DNA complex extraction technique of Zyzik et al., Eur J Chem Microbiol (1986) 5:330-335. FIG. 5 presents the analysis of the six DNA positive sera found in the set of 49 using 32 P nick translated pHE63 as a probe. Each sample was blotted and probed in duplicate directly (10°), diluted 1:10 (101) and 1:100 (102) in pooled normal human sera. Samples of pHE63 were blotted in duplicate in pooled normal sera or in buffer (10× SSC). Five separate blotting experiments of these sera with dilutions and plasmid standards were performed to establish the ranges calculated. These samples were used in the evaluation of the sandwich hybridization assay of the invention.

FIG. 6 presents the results obtained for the chemiluminescent readout format of the bead capture assay method with the HBV DNA positive samples described above. Analysis of a 4 pg sample of pHE63 is also shown. Two shaded values are given for each sample. The shaded bar represents the absolute signal (S) obtained for each sample and is expressed as the mean for two sets of triplicate samples (6 total samples). The open bar indicates the same number of control samples run on the same sera using beads that do not contain the Type C capture probe. This control, which is not possible in a blotting assay format, was used to determine nonspecific binding or noise (N) for each sample matrix that might lead to false positive signals. The specific signal for each sample can be expressed as the ratio of S and N as defined. An S/N ratio of 1 indicated no specific binding. Minimal S/N ratios indicating a positive sample are discussed below.

S/N ratios ranged from 3.9 to 49 for sera containing between 0.2 and 8 pg of HBV DNA. Assays conducted on two and four fold dilutions of sera 4825 and 3657 into pooled normal human sera resulted in a near linear decrease in the absolute signals for each sample, substantiating the presumed specific nature of the method. Excellent run to run reproducibility was found for all samples with different lots of beads and reagents. Although samples were read only 30 sec after addition of the chemiluminescent substrate solution, equivalent results were obtained for up to 45 min. Also, longer signal integrations did not improve S/N ratios. The sera employed ranged from cloudy to clear in appearance, were stored frozen and freeze-thawed many times. No attempt was made to clarify the samples prior to hybridization analysis. Increased solution hybridization or bead capture times (up to 18 h) did not significantly increase the S/N ratios.

In FIG. 7 the analysis of subpicogram HBV DNA samples are compared to known negative sera and large quantities of heterologous nucleic acids in pooled sera. Although the S value for the lowest positive serum employed (upper panel; 1 to 10 dilution of serum 3657) is slightly higher than the highest S for a negative serum (0092) or non-HBV DNA (HIV), no clear cutoff to differentiate between true and false positives below the pg level was possible based on absolute S alone. However, if the S/N was compared for these same samples (lower panel), a cutoff of S/N=2.5 permitted a clear distinction to be made. No negative sample had a value higher than 1.7, yet the lowest positive at 0.2 pg had an S/N=4.3. This clearly demonstrates the value of using a nonspecific binding control for each sample.

In FIG. 8, a comparison is made between an assay conducted on HBV DNA positive and negative sera using-both the luminol-p-hydroxycinnamic acid (given as relative luminescence, RL) and o-phenylenediamine (OPD) detection. Although the methods were comparable in sensitivity, the chemiluminescent method was preferred for several reasons. Firstly, using the bead format, the best colorimetric results were obtained by conducting the OPD reactions in Eppendorf tubes and transferring the solution to a microtiter dish for reading on an ELISA reader since the scattering from beads proved to be a significant source of background. In contrast, beads did not interfere with the chemiluminescent readout on the luminometer. Secondly, the chemiluminescent method was considerably faster. As opposed to waiting 30 min after addition of OPD before the detection, the chemiluminescent reactions could be read rapidly 30 sec after addition of the substrate. Lastly, there was a 1.5- to 2-fold increase in the S/N using RL versus OPD.

4. Sandwich Hybridization for N. gonorrhoeae DNA

Based on the N. gonorrhoeae pilin sequence described by Bergstrom, S., et al., Proc Natl Acad Sci USA (1986) 83:3890-3894, twelve amplifier DNA probes and three capture DNA probes were synthesized by the automated phosphoramidite method as described by Warner et al., supra. Purification was carried out according to Sanchez-Pescador and Urdea, supra. The 5'-portions of the probes were complementary to segments of the pilin sequence and were as follows:

__________________________________________________________________________Probe Designation      5'-Sequence__________________________________________________________________________AmplifierGCP-LLA2C-1      ATACTTATGGGAAGTTTTTCCGAAATGGGAGCP-LLA2C-2      GCTCGACTACTAACACTAGCGATAGCAGCCGCP-LLA2C-3      AAACCGCAATCAGCGGGAAGGGCGGATGGTGCP-LLA2C-5      GGAAAACCGGCTTCCAGTTTTTAGTCGGCAGCP-LLA2C-6      GCTCATAATGGACTTAAGGCCGTTTACCGGGCP-LLA2C-7      TTTGTTGTGAAGACGGCCGCACCGTAGGGGGCP-LLA2C-9      ACTTCAATTTTTGCCGCAGCAATGGCGGTGGCP-LLA2C-10      CGAAAGTTCGCCGCATTTGTTACTAATGTTGCP-LLA2C-11      GTTTTTTGAGAGGGACACCCGGTCCGCACTGCP-LLA2C-13      ATGCGCGTGGCTGCTGCTGTGGCAACGGCTGCP-LLA2C-14      GTTTCTGCCGTTTCTTTAGCTGTGGTTCGTGCP-LLA2C-15      CGGCAGTTGGACGGCGCTATTCCGTAGACTCaptureGCP-XT1-4  GATGTGGCGGGCGCGCGTTCAAAGGCTTCGGCP-XT1-8  GAGGCTGTAGTTTCCGTTTATACAATTTCTGCP-XT1-12 GCCAAGCCATTTTACCAAGACGCCTGTCGG__________________________________________________________________________

The 3'-portion of each amplifier probe was constructed to be complementary to the linear multimer of 2A above.

The 3'-portion of each capture probe was constructed to be complementary to the sequence of the oligonucleotide of the solid phase oligonucleotide complex of 3.B above.

Analyte DNA isolated from an N. gonorrhoeae strain, an N. meningitiditis strain, and several nonpathogenic commensal strains of Neisseria were tested using the N. gonorrhoeae amplifier and capture probes according to the assay format described in 3.G above. The results of these tests are reported in the table below.

______________________________________Assay Signal Response of Neisseria SpeciesSample                S/Na______________________________________Positiveb species:N. gonorrhoeae(1)      Clinical isolatesc                      6.8-187.0(2)      Geographical distributiond                     48.6-239.5N. meningitiditis(1)      Serogroup A (#9205)                     5.8(2)      Serogroup B (#9206)                     15.4(3)      Serogroup C (#9207)                     12.9(4)      Serogroup 29E (#9218)                     18.1(5)      Serogroup X (#9210)                     31.2(6)      Serogroup Z (#9211)                     15.5Negativeb species:N. meningitiditis(1)      Serogroup E (#9209)                     2.1(2)      Serogroup W135 (#9212)                     1.9N. cererea(1)      #36263           0.92(2)      #33683           0.76(3)      #32824           0.83(4)      #32828           0.99(5)      #30003           2.1N. lactamica(1)      #30011           0.92(2)      #36016           1.1(3)      #37168           1.7(4)      #37170           0.72(5)      #37174           0.97______________________________________ a Signal obtained with 6 × 106 to 2 × 108 cells. Noise was defined as the relative luminescence obtained for buffer alone. b A sample with a S/N > 3 was defined as positive; and a sample with a S/N < 3 was defined as negative. c Urethral swab samples, 46 male and 56 female, were obtained from Highland Hospital, Oakland, California. d Samples were obtained from Boston, Denver, New York, Indianapolis, Peoria, Portland, San Diego, San Francisco, Kentucky, Minnesota and North Carolina.

5. Sandwich Hybridization for N. gonorrhoeae Using Branched Amplification Probe

This example exemplifies the use of a branched amplifier probe or two multimers in hybridization assays: one that binds to the analyte; and a second that binds to the first and provides sites for binding labeled oligomers.

Twelve 5'-phosphorylated 40-base N. gonorrhoeae pilin specific probes were synthesized and purified. The sequences of these probes (probes 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14 and 15) are shown below and were designed to contain 30 unique bases complementary to the pilin gene (3'-end) and 10 common bases (5' end; pAGTACGTTTA).

Probe-1 pAGTACGTTTAAGGGTAAAGCCTTTTTGAAGGGTATTCATA

Probe-2 pAGTACGTTTACCGACGATAGCGATCACAATCATCAGCTCG

Probe-3 pAGTACGTTTATGGTAGGCGGGAAGGGCGACTAACGCCAAA

Probe-5 pAGTACGTTTAACGGCTGATTTTTGACCTTCGGCCAAAAGG

Probe-6 pAGTACGTTTAGGCCATTTGCCGGAATTCAGGTAATACTCG

Probe-7 pAGTACGTTTAGGGGATGCCACGCCGGCAGAAGTGTTGTTT

Probe-9 pAGTACGTTTAGTGGCGGTAACGACGCCGTTTTTAACTTCA

Probe-10 pAGTACGTTTATTGAATTCATTGTTTACGCCGCTTGAAAGC

Probe-11 pAGTACGTTTATCACGCCTGGCCCACAGGGAGAGTTTTTTG

Probe-13 pAGTACGTTTATCGGCAACGGTGTCGTCGTCGGTGCGCGTA

Probe-14 pAGTACGTTTATGCTTGGTGTCGATTTCTTTGCCGTCTTTG

Probe-15 pAGTACGTTTATCAGATGCCTTATCGCGGCAGGTTGACGGC

The common bases were used to incorporate by enzymatic ligation a common fork-type branched extension (5'-AGGCATAGGACCCGTGTCTTYTTYTTATCGTTATTC-3'; Y=5-methyl-N4 (6-hydroxyhexyl)deoxycytidine incorporated as the 5'-hydroxyl, N4 -hydroxyhexyl bis-dimethoxytrityl derivative; FTE-1) with a complementary linker, 5'-TAAACGTACTGAATAACGAT-3' (LINK-1). The capture probe set (probes 4, 8 and 12) were those described for the assay of 4 above.

The branched amplifier probes are synthesized by ligation and purification in batch 650 pmoles each of probes 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14 and 15, 7 nmoles of LINK-1, and 5.7 pmoles of FTE-1 as generally described in Meth Enzymol (1987) 146:22-41 to yield 934 pmoles of product.

An alkaline phosphatase labeled probe complementary to the 5'-secondary sequences of the branched amplifier probes was prepared according to section 3.G above.

Assays for N. gonorrhoeae were conducted using a pilin gene containing plasmid as described above. A total of 4-5 fmoles of each capture and amplifier probe was employed. A total of 200 fmoles of the multimer and the alkaline phosphatase-labeled probe were used. The procedure was identical to 4 except that no amplification step was used. For comparison purposes assays using the probe set of 4. above were run side-by-side. The results are shown below.

______________________________________        Signal  Noise     S/N______________________________________Comparison (4 above)           5.4 ± 0.3                    0.2 ± 0.02                              22.8 ± 2.0Branched amplifier system          10.6 ± 1.4                    0.1 ± 0.0                              75.8 ± 9.8______________________________________

A branched multimer was synthesized using the techniques described in 2.B above that contained both comb- and fork-type structural components. It was necessary to construct the molecule as described since a 5' extension of the forked amplifier probes was required to maximize binding to the branched labeling probe set (as opposed to the 3' extension described above). The multimer had the following structure ##STR11## where Y is defined as above and O=5-methyl-N4 (6-hydroxyhexyl)deoxycytidine incorporated as the 5'-O-dimethoxytrityl, N4 -O-FMOC derivative of 5-methyl-N4 (6-hydroxyhexyl)deoxycytidine. The branched amplifier probe and branched multimer described above are depicted schematically in FIG. 9.

Assays for N. gonorrhoeae were conducted as described above with an amplification step. Side-by-side analyses with the probe set of 4 were also performed. The results are given below.

______________________________________        Signal  Noise     S/N______________________________________Comparison (4 above)           5.5 ± 0.8                    0.3 ± 0.03                              21.0 ± 3.8Two multimer system          17.3 ± 1.7                    0.4 ± 0.1                              45.5 ± 12.2______________________________________

6. Sandwich Hybridization Test for TEM-1 beta-Lactamase DNA in N. gonorrhoeae

Molecular analyses have revealed that the penicillin resistance observed in N. gonorrhoeae is mostly due to the presence of a TEM-1 beta-Lactamase gene in a non-conjugative plasmid of 3-7 Mdal. (This plasmid is homologous to those found in H. ducreyi, H. parainfluenzae, and occasionally H. influenzae.) Probes were thus developed to detect TEM-1DNA in N. gonorrhoeae (or the other mentioned bacteria carrying homologous plasmids) for the purpose of determining penicillin resistance.

The 7.3 Kb N. gonorrhoeae plasmid carrying the TEM-1 gene was obtained as described by Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (1982). This plasmid was transformed into E. coli HB101 and purified. The plasmid was digested with BamHI and a 2390 bp BamHI fragment was purified and partially sequenced. A total of 1811 bp were sequenced, corresponding to 80% of the structural TEM-1 gene and 1181 bp of adjacent sequences from the H. parainfluenzae plasmid related to pHPA300 DNA. The sequenced portion is shown in FIG. 10.

Amplifier probes and capture probes were synthesized and purified by the procedures described above. The 5'-portions of the amplifier probes were complementary to sequences of the coding region; whereas the 5'-portions of the capture probes were complementary to sequences of pHPA300. The sequences of the probes are shown in FIG. 11.

Amplifier and capture probes were also prepared using a similar strategy to that used for the HBV and N. gonorrhoeae probes in which both sets of probes are directed to the TEM-1 gene. The sequences of these probes are shown in FIG. 12.

The assay format of 3.G. above was used to assay crude cellular lysates from different bacteria. The results of these tests are tabulated below with the designations "TEM-1" indicating tests using the probes directed only to the TEM-1 gene and "TEM-1NH" indicating the tests where the probes are directed, respectively, to the TEM-1 gene and pHPA300 sequences.

              TABLE 2______________________________________Screening of Penicillin-Resistant Bacteria          TEM-1         TEM-1NHSpecies          Pos.   Neg.     Pos. Neg.______________________________________Neisseria gonorrhoeae            2      0        97   0Haemophilus parainfluenzae1            .sup. nd2                   nd       3    0Haemophilus influenza3            2      0        0    2Haemophilus ducreyi            nd     nd       3    0Salmonella typhi 2      0        0    2Shigella sonnei  1      0        0    1Branhamella catarrhalis            0      4        0    4Escherichia coli 1      0        0    1______________________________________ 1. Isolated from respiratory tract. 2. Not determined. 3. Isolated from genital tract.

Based on the above tests and additional tests, the specificities of the TEM-1 and TEM-1NH assays may-be defined as follows:

Penicillin Resistant Organisms Positive with the TEM-1 Assay: Penicillinase Producing Neisseria gonorrhoeae (PPNG), H. influenzae, H. parainfluenzae, S. typhi, S. sonnei, E. coli.

Penicillin Resistant Organisms Positive with the TEM-1NH Assay: PPNG, H. influenzae, H. parainfluenzae, H. ducreyi.

Penicillin Resistant Organisms Negative with the TEM-1NH Assay: H. influenzae, S. typhi, S. sonnei, E. coli, B. catarrhalis non-TEM-1 βl -lactamase.

Penicillin Sensitive Organisms Negative with the TEM-1NH Assay: N. gonorrhoeae, B. catarrhalis, H. ducreyi, N. cinerea, Clostridium albians, N. lactamica, N. mucosa, N. sicca, N. subflava, N. meningitidis, H. influenzae, Streptococcus faecalis, Mycoplasma hominis, Treponema pallidum.

This TEM-1 assay is thus a powerful clinical tool that will enable medical personnel to identify penicillin-resistant infections and prevent treatment failure by choosing the appropriate antibiotic for therapy.

7. Sandwich Hybridization for Chlamydia trachomatis

A. Probes/Multimers

Amplification and capture probe sets were prepared using the same strategy as that used to prepare the HBV and TEM-1 probes and were designed to hybridize to the Chlamydia pCHL2 plasmid. (Palmer and Falkow, Plasmid (1986) 16:52-62.) Each probe of the set was a 50 mer, with the first 30 nucleotides (5' to 3') being complementary to pCHL2 sequences and the last 20 nucleotides being the amplifier and capture sequences used in the TEM-1 and TEM-1NH assays. The pCHL2 sequences for these probes are given below:

__________________________________________________________________________Probe Designation       Sequence (3' to 5')__________________________________________________________________________AmplifierpCHL2.C LLA2C-2       CTACTAAACTCGCACACATCGCGACTTCTTpCHL2.C LLA2C-3       AACTCATTAAAGTAAAAGGCGAGCAAATTApCHL2.C LLA2C-4       ATGTTACTTTTAGGTAACGCATCTAGAGGCpCHL2.C LLA2C-6       TCACGATATCGTTTCTGAAAAAGATAAGCGpCHL2.C LLA2C-7       CGATCTCCGGCCAGATAAATACTATATAAGpCHL2.C LLA2C-8       GTCAGTCTTTAACCTCACGACCGAGCATATpCHL2.C LLA2C-10       AGAAAGAAACTACGGAAGGGTTGTCCTATGpCHL2.C LLA2C-11       CTATAACTACTATTTCCTCAATAGAATCGApCHL2.C LLA2C-12       CCATTAAAGCACTAATATCGTCGATCCGGTpCHL2.C LLA2C-14       TATTTAGAACGCCAATGAGTTGTCGCATCTpCHL2.C LLA2C-15       CCAAAGGATAGAGATCTTTACTCGCGTCCApCHL2.C LLA2C-16       TAACAACTCGCCTAATAACGATTAAATTGTpCHL2.C LLA2C-18       AGATTTCTTCTTAATAAGGCTCATCTTCTTpCHL2.C LLA2C-19       CCTCTTTGTCAATCTCTTAGTGTAAAAATACapturepCHL2.CXTI-1       TTCGAATCTAGGCAAAGAGTATGCCAAAAGpCHL2.CXTI-5       GATAACGAACTCGCATATTTCCCTTCCGAApCHL2.CXTI-9       TTTTCTGCTCGTTGCAAGAGACTCTTAGTTpCHL2.CXTI-13       TATCCCTTTTGACGAAATCGATATCTGTACpCHL2.CXTI-17       TATAGACCACTTTTTAATGTTTCTCCCCTA__________________________________________________________________________

B. Samples Tested and Results

Assays were performed on isolated elementary bodies (EB) of Serovar L2. The concentration of EB in standard samples was determined by spreading dilutions in 1× PBS onto a slide and staining with the Syva Microtrak Immunofluorescence Kit. By microscopic examination, six random fields were counted and the total EB per ml was calculated.

The sample preparation procedure for Chlamydia differed from the HBV or Neisseria. One of two methods was employed: 12.5 μl of either (1) lysozyme (4 mg/ml in 50 mM glucose, 25 mM Tris, pH 8.0, 10 mM EDTA) or (2) 10 mM DTT in 1× PBS was added to each well containing 10 μl of sample. After incubation at 65° C. for 30 min, 1.2 μl of 10% SDS was added. The assay was then conducted as described above. Prior to the capture step, 10 μl of horse serum was added to the N and S wells. Also, for the amplification and labeling steps, horse serum instead of water was used in the HM buffer. The alkaline phosphatase/phosphate dioxetane system was employed for detection, as above. The results were as follows.

______________________________________Number of EB  Signal______________________________________  3 × 106         22.67 +/- 1.63  6 × 105         5.39 +/- 0.12  3 × 105         2.07 +/- 0.111.5 × 105         1.63 +/- 0.030             0.57 +/- 0.06______________________________________

8. Sandwich Hybridization Test for tetM Determinant in N. gonorrhoeae

N. gonorrhoeae strains resistant to high levels of tetracycline resistance exhibiting MIC (minimum inhibitory concentration) values above 16 μg/ml have been found to have acquired the term determinant in a 24.5 Md conjugative plasmid (Annual Review of Microbiology (1984) 38:111-133 and Antimicrobe Agents Chemother. (1986) Vol 30:664-670). An assay was thus developed to detect the tetM determinant in N. gonorrhoeae to permit direct diagnosis of tetM mediated tetracycline resistance in clinical samples. The assay allows detection of term from large numbers of samples, gives "same day" results, and is capable of detecting as few as 15×103 cells.

Ten μl of tetracycline resistant N. gonorrhoeae (TRNG) cells suspended in either GC broth or skimmed milk were mixed with 12.5 ul of lysis solution (2 mg/ml proteinase K in 10 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 1% SDS, pH 8.0) in a clear Immulon II well (Dynatech), and incubated at 65° C. for 20 min.

Amplification and capture probes sets were prepared using the same strategy as that used to prepare the HBV and TEM-1 probes and were designed to hybridize to the tetM structural gene. The sequences of the probes were based on the tetM gene sequence from the streptococcal conjugative shuttle transposon Tn1545 described in Nucleic Acids Research (1986) 14:7047-7058. The sequence of the tetM gene together with the capture probe (A) and amplifier probe (B) sequences are shown in FIG. 13. Each probe was a 50 mer with the first 30 nucleotides (5' to 3') being complementary to the tetM gene (as shown in FIG. 13) and the last 20 nucleotides (extended at the 3' end) being CTTCTTTGGAGAAAGTGGTG for the capture probes and TTAGGCATAGGACCCGTGTC for the amplifier probes.

The test procedure was similar to the microtiter dish assay procedure of 3.G. above. Five μl of 1M NaOH containing 0.2 pm of each capture and labeling probes were added and the mixture was incubated at 65° C. for 20 min. Thirteen μl of neutralizing solution (2M MOPS, 12.3× SSC (1× SSC=0.15M NaCl, 15 mM sodium citrate) were added and the mixture was incubated at 65° C. for 15 min. After ten μl of heat inactivated horse serum was added to each well, the solutions were mixed and transferred to Immulon I white wells previously coated with a synthetic oligonucleotide complementary to the capture probes. The wells were incubated at 65° C. for 2 hours after which the mixture was removed from the wells and discarded. The wells were washed twice with 0.1% SDS, 0.1× SSC. Forty μl of a solution of amplification multimer (see 3.G. above) were added and the wells were incubated at 55° C. for 15 min. The wells were then washed twice as above and 40 μl of an alkaline phosphatase labeled oligonucleotide probe (see 3.G. above) solution were added. The wells were further incubated at 55° C. for 15 min, washed twice as above and washed twice with 0.1× SSC. Detection was achieved with a dioxetane chemiluminescent substrate (see 3.G. above). Luminescence was recorded either by using a microtiter dish reading luminometer (Dynatech) or by exposing the wells at Polaroid 57 instant black and white film in a dark chamber at 37° C. for 10 min. The signal to noise ratio (S/N) is defined as the light counts emitted by a well containing a sample divided by the light counts emitted by a well containing buffer alone. A sample was considered positive when the S/N ratio was ≧3.

For comparison, tetracycline sensitive (Tcs) strains and commensal strains known to carry tetM were also tested. The table below presents the results of the tests.

______________________________________            tetM     tetMstrain1     positive negative______________________________________N. gonorrhoeae   132      0N. gonorrhoeae(Tcs)            0        45N. mucosa        4        0N. mucosa/perflava            1        0N. perflava/sicca            9        0K. denitrificans 3        0E. corrodens     1        0______________________________________ 1.All organisms were resistant to tetracycline (MIC ≧ 16 μg/ml) except where indicated.

As shown in the table, a total of 132 TRNG strains were tested using the tetM hybridization assay. All of these strains showed positive values when read with the luminometer or with instant film. Commensal strains known to carry tetM, such as N. mucosa, N. mucosa/perflava, N. perflava/sicca, Kingella denitrificans and Eikenella corrodens, were also positive in the assay. On the other hand, none of the 45 Tcs strains tested showed positive values.

This assay may be used to detect any tetM mediated tetracycline resistant organism. By designing the capture and amplifier probes to bind to both the tetM gene and the 24.5 Md plasmid in an appropriate arrangement (as in the TEM-1NH assay described above), reactivity may be limited to TRNG. The use of the tetM test, together with the TEM-1 test reported above considerably reduces the time required to screen for antibiotic resistant micro-organisms where TEM-1 or tetM mediated resistance is suspected. These procedures obviate the need for sub-culturing primary cultures in the presence of the appropriate antibiotic. These assays require minimal sample preparation and involve very simple manipulations similar to ELISA procedures. In combination with the assay for N. gonorrhoeae, detection of N. gonorrhoeae and antibiotic resistance characterization can be conducted in a few hours. All the components of the assay, including the microtiter wells, are universal (analyte independent) with the exception of the capture and amplifier probes. As a result, the simultaneous analysis of a sample for the infectious agent and the antibiotic resistance can be performed in parallel, within the same time frame, and with the same manipulations.

9. Sandwich Hybridization Assay for N. gonorrhoeae DNA using Probes Based on N. gonorrhoeae Genomic Sequence SSJK1.

A new genomic sequence designated SSJK1 having a high degree of specificity for N. gonorrhoeae was identified by screening genomic clones against N. gonorrhoeae DNA and N. meningitidis DNA and selecting sequences that reacted with the former but not the latter. The DNA sequence of SSJK1 is shown in FIG. 14. This sequence was checked against available DNA libraries and has not been reported previously.

Based on the SSJK1 sequence, capture and amplifier probes were synthesized as in section 4 above. The 5' portions of the sequences are shown in FIG. 15. The 3' portions of the sequences were the same as those described in the TEM-1 assay described above (see FIG. 12). Both 5' portions and 3' portions are shown in FIG. 15. The assay format of 3.G. above was used to assay crude cellular lysates and genomic DNA from different bacteria. The results of tests with DNA samples are tabulated below.

______________________________________Sample                  S/N______________________________________1) Negative samplesaa)     Branhamella catarrhallis                       0.97b)     Neisseria sicca      1.12c)     Neisseria subflava   1.08d)     Neisseria mucosa     1.02e)     Neisseria lactamica  1.94f)     Neisseria flavescens 1.09g)     Neisseria cinerea (#33683)                       2.21h)     Neisseria cinerea (#32828)                       2.23i)     Neisseria meningitidis, serogroup A                       1.94j)     Neisseria meningitidis, serogroup B                       1.12k)     Neisseria meningitidis, serogroup C                       1.19l)     Neisseria meningitidis, serogroup D                       0.922) Positive samplesbNeisseria gonorrhoeae   3.67-26.64(17 strains represeenting variousserotypes were tested)______________________________________ a Samples with an S/N < 3 were defined as negative. All negative samples were tested using 10 μg of genomic DNA. b Samples with an S/N > 3 were defined as positive. All positive samples were tested using 100 ng of genomic DNA.

Due to the specificity of the SSJK1 sequence for N. gonorrhoeae it will be appreciated that probes based upon the entire sequence or fragments thereof may be used in other DNA hybridization assays. Accordingly, in general DNA probes based upon the SSJK1 sequence are intended to be within the invention. Such probes may be labeled directly or indirectly depending upon the particular hybridization assay format used.

10. HBV Subtype Non-specific Sandwich Hybridization Assays

Extensive comparison of the assay designed for adw HBV subtype described in part B of the results section of Example 3 above against dot blots using a 32 p labeled strain adw HBV probe containing the entire genome on samples obtained in the United States revealed that the former gave a small number of false negatives. Further comparative testing of samples obtained from Japan exhibited an even greater significance of false negatives. These results indicated that it was possible that the relatively short oligonucleotide probes used in the hybridization assay were not binding to some of the samples due to strain variation at the DNA level (i.e., the samples included non-adw subtypes that varied enough to affect the binding with the oligonucleotide probes).

Accordingly, the capture and amplifier probe sets were redesigned from a computer comparison of the nucleotide sequences of the nine HBV subtypes reported in Gene Bank. These probes (subtype non-specific, SN) are of varying length and were permitted to contain up to a 32-fold level of degeneracy (multiple nucleotides in various positions). Their 3' sequences are shown in FIG. 16. As indicated, these sequences were extended with the LLA2C and XTI 20-mers shown in FIG. 11.

Assays using these redesigned probes were compared with assays using the probes of Example 3 (adw) and dot blot. (The microtiter dish MTD format was used in the sandwich hybridizations.) The results are given below.

______________________________________Genomic Dot Blot   adw MTD   SN MTD______________________________________H 35   +++             ++        +++H 36   ++              ++        +++H 33   ++              ++        +++H 34   ++              +         +++H 32   +++             -         +++H 18   ++              -         ++H 21   ++              -         ++H 22   ++              -         +++H 23   ++              -         +++H 24   ++              -         ++H 25   ++              -         ++H 27   ++              -         ++H 28   ++              -         ++H 31   ++              -         +3      +++             -         ++5      ++              -         +6      ++              -         +15     +++             -         +++17     +++             -         ++42     ++              -         +++48     ++              -         +++adr    +               -         +adw    +               +         +______________________________________

As mentioned, the adw assay negative samples were positive in the SN assay and genomic dot blot--indicating the samples are subtype other than adw. A sample of known adr subtype was employed as a control.

It will be appreciated that the invention assay may be adapted to conduct multiple assays for different analytes simultaneously. In one format, by changing the label and the labeling probe sequences, amplification multimer and labeled probe sequences for a new analyte, it should prove possible to detect two different analytes in the same sample on the same solid phase. Alternatively, by synthesizing analyte specific capture probe and attaching the specific complementary capture probes to different positions on a membrane strip, it is possible to perform several different assays simultaneously with the same label.

Due to the low interference observed from the presence of heterologous nucleic acids and sample components, the invention method presented here is useful in the detection of a variety of organisms in crude materials with minimal sample preparation. Except for the solution phase hybridization probes which are unmodified synthetic oligonucleotides, all assay components are universal (analyte sequence independent); therefore, a new assay simply requires a new set of oligonucleotides. In principle, the chemiluminescent form of the analysis system presented is sufficiently sensitive to permit single gene detection in 5 μg of mammalian DNA in 4 h.

Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in nucleic acid chemistry, biochemical assays, and related fields are intended to be within the scope of the following claims.

Patentzitate
Zitiertes PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US4299916 *26. Dez. 197910. Nov. 1981Syva CompanyColorimetric analysis of analytes
US4428941 *29. Aug. 198031. Jan. 1984Institut PasteurNucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby
US4563419 *29. Dez. 19837. Jan. 1986Orion Corporation Ltd.Detection of microbial nucleic acids by a one-step sandwich hybridization test
US4749647 *22. Juni 19847. Juni 1988Genetic Systems CorporationPolymerization-induced separation assay using recognition pairs
US4828979 *8. Nov. 19849. Mai 1989Life Technologies, Inc.Biotinylated
US4882269 *11. Dez. 198621. Nov. 1989Princeton UniversityAmplified hybridization assay
US4894325 *15. Jan. 198716. Jan. 1990Enzo Biochem, Inc.Targets, polynucleotied, genetic engineering
US4910300 *5. Mai 198820. März 1990Chiron CorporationMethod for making nucleic acid probes
US5124246 *18. Apr. 198923. Juni 1992Chiron CorporationImproved hybridization assays for hepatitis B virus, Neissera gonorrhoeae, penicillin and tetracycline resistance in N. gonorrhoeae and Chlamydia trachomatis
EP0225807B1 *10. Dez. 198619. Okt. 1994Chiron CorporationSolution phase nucleic acid sandwich assay and polynucleotide probes useful therein
WO1987006270A1 *15. Apr. 198722. Okt. 1987Salk Inst For Biological StudiReplicative rna reporter systems
WO1990002819A1 *6. Sept. 198922. März 1990Salk Inst For Biological StudiReplicative rna-based amplification detection systems
Nichtpatentzitate
Referenz
1Chu et al., "Synthesis of an amplifiable reporter RNA for bioassays" Nucleic Acids Research (1986) 14(14):5591-5603.
2 *Chu et al., Synthesis of an amplifiable reporter RNA for bioassays Nucleic Acids Research (1986) 14(14):5591 5603.
3 *Damha et al. (1989) Tetrahedron Letters, vol. 30, No. 46, pp. 6295 6298.
4Damha et al. (1989) Tetrahedron Letters, vol. 30, No. 46, pp. 6295-6298.
5 *Kierzek et al. (1986) Nucleic Acids Research, vol. 14, No. 12, pp. 4751 4764.
6Kierzek et al. (1986) Nucleic Acids Research, vol. 14, No. 12, pp. 4751-4764.
7Syvanen et al., "Fast quantification of nucleic acid hybrids by affinity-based hybrid collection" Nucleic Acids Research (1986) 14(12):5037-5048.
8Syvanen et al., "Quantification of polymerase chain reaction products by affinity-based hybrid collection" Nucleic Acids Research (1988) 16(23):11327-11338.
9 *Syvanen et al., Fast quantification of nucleic acid hybrids by affinity based hybrid collection Nucleic Acids Research (1986) 14(12):5037 5048.
10 *Syvanen et al., Quantification of polymerase chain reaction products by affinity based hybrid collection Nucleic Acids Research (1988) 16(23):11327 11338.
Referenziert von
Zitiert von PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US620398925. März 199920. März 2001Affymetrix, Inc.Methods and compositions for amplifying detectable signals in specific binding assays
US6214549 *8. Okt. 199610. Apr. 2001Roche Diagnostics GmbhContacting sample with probe comprising stem and branch such that substance if present binds directly or indirectly to probe; mixing binding product with conjugate; removing unbound conjugate from mixture; determining presence of conjugate
US6235889 *8. März 199922. Mai 2001University Of ChicagoLibraries; polymerase chain reaction
US650371416. Nov. 20007. Jan. 2003Roche Diagnostics GmbhMethod of detecting a substance to be analyzed
US650689621. Sept. 199814. Jan. 2003Nanogen Recognomics GmbhConjugated to peptides, proteins, nucleic acids, antibodies, RNA, or DNA; medical diagnosis, electronics
US65451347. Apr. 19998. Apr. 2003Nanogen Recognomics, Gmbh.Method for the production of pentopyranosyl nucleosides
US661389421. Sept. 19982. Sept. 2003Nanogen Recognomics GmbhBonding the nucleoside to a solid support, deprotecting using an acid, reacting with a nucleoside phosphoramidite; oxidizing and coupling a biomolecule to the product
US669997821. Sept. 19982. März 2004Nanogen Recognomics GmbhLinker nucleoside, and production and use of the same
US68060476. Febr. 200119. Okt. 2004Affymetrix, Inc.Methods and compositions for amplifying detectable signals in specific binding assays
US71958717. Nov. 200227. März 2007Third Wave Technologies, IncCleaving with nucleases; forensic analysis and paternity testing
US72977806. Jan. 200420. Nov. 2007Third Wave Technologies, Inc.nucleotides/phosphoramidite linkages; solid phase synthesis
US73547069. März 20068. Apr. 2008The Regents Of The University Of Colorado, A Body Corporatecontacting photoinitiator-labeled target-probe complex with polymer precursor, exposing to light; biotin, streptavidin, DNA, influenza; replace PCR and bacteria culturing
US74624481. Aug. 20039. Dez. 2008Stratatech CorporationUsing vector specific repetitive sequences to confirm transfer of vector to cells; genetic engineering and heterologous gene transfer; identifying mouse cells in immortilization cultures
US746245126. Apr. 20059. Dez. 2008Third Wave Technologies, Inc.nucleotides/phosphoramidite linkages; solid phase synthesis
US747355120. Mai 20056. Jan. 2009Atonomics A/SNano-mechanic microsensors and methods for detecting target analytes
US76187782. Juni 200517. Nov. 2009Kaufman Joseph CProducing, cataloging and classifying sequence tags
US764544120. März 200212. Jan. 2010Sagres Discovery Inc.Compositions and methods in cancer associated with altered expression of PRLR
US770027420. März 200220. Apr. 2010Sagres Discovery, Inc.Compositions and methods in cancer associated with altered expression of KCNJ9
US770076131. Mai 200620. Apr. 2010Nanogen Recognomics Gmbh3-deoxypentopyranosyl nucleic acid, its production and its use
US776738713. Juni 20033. Aug. 2010Sagres Discovery, Inc.Therapeutic targets in cancer
US781607624. Okt. 200519. Okt. 2010Sagres Discovery, Inc.Therapeutic targets in cancer
US782044726. Dez. 200126. Okt. 2010Sagres Discovery Inc.drug screening; for carcinomas, especially lymphoma carcinomas
US782485922. Juni 20062. Nov. 2010Cytyc Corporationgenerating a signal indicative of the presence of a target nucleic acid in a sample by forming a cleavage structure through incubating a sample with a probe containing a binding moiety and having a secondary structure that changes upon binding and cleaving the cleavage structure with a nuclease
US783822522. Juni 200623. Nov. 2010Hologic, Inc.Generating a signal indicative of the presence of a target nucleic acid in a sequence by incubating the sample containing the target with a reverse transcriptase, a primer and a probe
US784666129. Nov. 20067. Dez. 2010Hologic, Inc.Methods of detecting an amplified nucleic acid
US78884965. Dez. 200815. Febr. 2011Stratatech CorporationKit for species specific DNA detection
US78927301. März 200222. Febr. 2011Sagres Discovery, Inc.Nucleotide sequences coding polypeptide for use in the treatment of and detection of cancer
US808038023. Juli 200420. Dez. 2011Illumina, Inc.Use of microfluidic systems in the detection of target analytes using microsphere arrays
US81145969. Okt. 200914. Febr. 2012Kaufman Joseph CProducing, cataloging and classifying sequence tags
US81903718. Sept. 200829. Mai 2012Third Wave Technologies, Inc.Methods and applications for target quantification
US82069041. Juni 200726. Juni 2012Third Wave Technologies, Inc.Detection of nucleic acids
US839494415. Sept. 200312. März 2013Siemens Healthcare Diagnostics Inc.for detection and quantitation of single nucleotide polymorphisms (SNPs) using polymerase chain reaction (PCR); kits
US848126817. Nov. 20119. Juli 2013Illumina, Inc.Use of microfluidic systems in the detection of target analytes using microsphere arrays
US84815065. Dez. 20079. Juli 2013Rosetta Genomics, Ltd.Nucleic acids involved in viral infection
US8494780 *2. Febr. 201023. Juli 2013Lawrence Livermore National Security, LlcData transformation methods for multiplexed assays
US85246796. Nov. 20073. Sept. 2013Veritas Bio, LlcIn vivo delivery of double stranded RNA to a target cell
US860418226. Febr. 201010. Dez. 2013Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
US86527788. Apr. 201118. Febr. 2014The Regents Of The University Of Colorado, A Body CorporateUse of photopolymerization for amplification and detection of a Molecular Recognition Event
US865836121. Okt. 201125. Febr. 2014Advanced Cell Diagnostics, Inc.Ultra sensitive method for in situ detection of nucleic acids
US868564618. Dez. 20091. Apr. 2014Siemens Healthcare Diagnostics Inc.Methods and reagents for shortening incubation times in hybridization assays
US876206828. Okt. 200924. Juni 2014Lawrence Livermore National Security, LlcMethods for threshold determination in multiplexed assays
US880899011. Mai 201219. Aug. 2014Exact Sciences CorporationSerial isolation of multiple DNA targets from stool
US20110022344 *2. Febr. 201027. Jan. 2011Tammero Lance F BentleyData transformation methods for multiplexed assays
DE202004021633U117. Juni 200426. Nov. 2009Illumina, Inc., San DiegoZusammensetzungen zur Gesamtgenom-Amplifikation und Genotypisierung
EP1923471A120. Apr. 200021. Mai 2008Illumina, Inc.Detection of nucleic acid reactions on bead arrays
EP2014669A228. Febr. 200314. Jan. 2009Sagres Discovery, Inc.Compositions and methods for cancer
EP2031076A127. Febr. 20034. März 2009Sagres Discovery, Inc.Novel compositions and methods for cancer
EP2034030A226. Dez. 200211. März 2009Sagres Discovery, Inc.Novel compositions and methods for cancer
EP2058408A217. Febr. 200413. Mai 2009Sagres Discovery, Inc.Therapeutic GPCR targets in cancer
EP2062591A17. Apr. 200627. Mai 2009Novartis Vaccines and Diagnostics, Inc.CACNA1E in cancer diagnosis detection and treatment
EP2083088A27. Apr. 200629. Juli 2009Novartis Vaccines and Diagnostics, Inc.Cancer-related genes
EP2093233A121. März 200326. Aug. 2009Sagres Discovery, Inc.Novel compositions and methods in cancer
EP2204376A220. Juli 20057. Juli 2010Sagres Discovery, Inc.Novel therapeutic targets in cancer
EP2253643A112. März 200324. Nov. 2010Sagres Discovery, Inc.Novel compositions and methods in cancer associated with altered expression of PRLR
EP2264188A117. Juni 200422. Dez. 2010Illumina, Inc.Methods and compositions for whole genome amplification and genotyping
EP2264189A120. Apr. 200022. Dez. 2010Illumina, Inc.Detection of nucleic acid reactions on bead arrays
EP2301954A29. Mai 200330. März 2011Agensys, Inc.Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer
EP2302041A17. Nov. 200230. März 2011Agensys, Inc.Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP2319524A128. Mai 200411. Mai 2011Agensys, Inc.Prostate stem cell antigen (PSCA) variants and subsequences thereof
EP2322650A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322651A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322652A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322653A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322654A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322660A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322662A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2322665A114. Mai 200518. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2325331A114. Mai 200525. Mai 2011Rosetta Genomics LtdMicroRNAs and Uses Thereof
EP2325333A114. Mai 200525. Mai 2011Rosetta Genomics LtdMicrorRNAs and uses thereof
EP2325340A114. Mai 200525. Mai 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2327798A114. Mai 20051. Juni 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2332966A123. Apr. 200315. Juni 2011Agensys, Inc.Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
EP2336363A114. Mai 200522. Juni 2011Rosetta Genomics LtdMicroRNAs and uses thereof
EP2343315A210. Febr. 200413. Juli 2011Agensys, Inc.Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
EP2361991A118. Dez. 200331. Aug. 2011Third Wave Technologies, Inc.Detection of small nucleic acids
EP2428522A117. Mai 200514. März 2012Agensys, Inc.Antibodies that bind to PSCA proteins for diagnosis of cancer
EP2460893A119. Juni 20066. Juni 2012Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2511708A12. Okt. 200817. Okt. 2012Affymetrix, Inc.Highly multiplexed particle-based assays
EP2522751A11. Juni 200714. Nov. 2012Third Wave Technologies, Inc.Detection of nucleic acids
EP2548438A16. Nov. 200723. Jan. 2013Veritas Bio, LLCIn vivo delivery of double stranded RNA to a target cell
EP2583981A217. Mai 200524. Apr. 2013Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
EP2711434A119. Juni 200626. März 2014Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
WO1998030719A1 *7. Jan. 199816. Juli 1998Biogenex LabMultifunctional linking reagents for synthesis of branched oligomers
WO2000004192A1 *16. Juli 199927. Jan. 2000David A ShaferMethods for detecting and mapping genes, mutations and variant polynucleotide sequences
WO2000063437A220. Apr. 200026. Okt. 2000Illumina IncDetection of nucleic acid reactions on bead arrays
WO2001046464A1 *21. Dez. 200028. Juni 2001Reinhold HillerBranched compound for use in nucleic acid detection and analysis reactions
WO2002033125A1 *20. Sept. 200125. Apr. 2002Datascope Investment CorpNucleic acid detection by dendrimeric labeling
WO2005118864A217. Mai 200515. Dez. 2005Agensys IncAntibodies and related molecules that bind to psca proteins
WO2011038403A128. Sept. 201031. März 2011Yuling LuoMethods of detecting nucleic acid sequences with high specificity
WO2013078283A121. Nov. 201230. Mai 2013Intermune, Inc.Methods of diagnosing and treating idiopathic pulmonary fibrosis
WO2013184553A13. Juni 201312. Dez. 2013Gen-Probe IncorporatedCompositions and methods for amplifying and characterizing hcv nucleic acid
WO2014074785A18. Nov. 201315. Mai 2014Ludwig Institute For Cancer Research Ltd.Methods of predicting outcome and treating breast cancer
Klassifizierungen
US-Klassifikation435/6.11, 536/24.1, 536/22.1, 536/24.31, 536/24.3, 536/24.32, 435/810, 436/501, 435/7.1, 536/23.1, 536/24.33
Internationale KlassifikationC07H19/06, C07H21/00, G01N33/532, C12Q1/70, C12Q1/68
UnternehmensklassifikationC07H19/06, Y10S435/948, C07H21/00, G01N2333/045, G01N33/532, Y10S435/81, C12Q1/682, Y10S436/811, C12Q1/706, C12Q1/689
Europäische KlassifikationC07H19/06, C07H21/00, C12Q1/68B2D, C12Q1/70B6, C12Q1/68M10B, G01N33/532
Juristische Ereignisse
DatumCodeEreignisBeschreibung
3. Juni 2010ASAssignment
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:24474/810
Effective date: 20070101
Owner name: SIEMENS HEALTHCARE DIAGNOSTICS INC.,NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:024474/0810
2. Juni 2010ASAssignment
Owner name: BAYER CORPORATION,PENNSYLVANIA
Free format text: MERGER;ASSIGNOR:CHIRON DIAGNOSTICS CORPORATION;REEL/FRAME:24468/567
Effective date: 19990305
Free format text: MERGER;ASSIGNOR:CHIRON DIAGNOSTICS CORPORATION;REEL/FRAME:024468/0567
5. Sept. 2008FPAYFee payment
Year of fee payment: 12
29. Okt. 2004FPAYFee payment
Year of fee payment: 8
27. Okt. 2000FPAYFee payment
Year of fee payment: 4
22. Jan. 1999ASAssignment
Owner name: CHIRON DIAGNOSTICS CORPORATION, MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHIRON CORPORATION;REEL/FRAME:009678/0915
Effective date: 19990122